<!doctype html>
<meta charset="utf-8">
<title>Aspirin - Wikipedia, the free encyclopedia</title>
<body>
<br>
<br>
<br>

<h1>Aspirin</h1>  From Wikipedia, the free encyclopedia <br>
<br>
 Jump to: 
navigation, search <br>
 &quot;Asprin&quot; redirects here. For the author, see 
Robert Asprin. <br>
<br>
 Aspirin <br>
<br>
Systematic (IUPAC) name <br>

2-acetoxybenzoic acid <br>
Clinical data <br>
AHFS/Drugs.com monograph <br>

MedlinePlus a682878 <br>
Pregnancy cat. C(AU) D(US) <br>
Legal status U
nscheduled (AU) GSL (UK) OTC (US) <br>
Routes Most commonly oral, also rectal. 
Lysine acetylsalicylate may be given IV or IM <br>
Pharmacokinetic data <br>

Bioavailability Rapidly and completely absorbed <br>
Protein binding 99.6% <br>

Metabolism Hepatic <br>
Half-life 300&ndash;650&nbsp;mg dose: 3.1&ndash;3.2 h
<br> 1 g dose: 5 h<br>
 2 g dose: 9 h <br>
Excretion Renal <br>
Identifiers <br>
CAS number 50-78-2&nbsp;Y <br>
ATC code A01AD05 B01AC06, N02BA01 <br>
PubChem 
CID 2244 <br>
DrugBank DB00945 <br>
ChemSpider 2157&nbsp;Y <br>
UNII R16CO5Y76E
&nbsp;Y <br>
KEGG D00109&nbsp;Y <br>
ChEBI CHEBI:15365&nbsp;Y <br>
ChEMBL 
CHEMBL25&nbsp;Y <br>
Synonyms 2-acetyloxybenzoic acid<br>
 acetylsalicylate<br>

 acetylsalicylic acid<br>
 O-acetylsalicylic acid <br>
Chemical data <br>

Formula C9H8O4&nbsp; <br>
Mol. mass 180.157 g/mol <br>
SMILES eMolecules &amp; 
PubChem <br>
InChI <br>

<ul> 
<li> 
<p>InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)&nbsp;Y
<br> Key:BSYNRYMUTXBXSQ-UHFFFAOYSA-N&nbsp;Y</p> </li> </ul> <br>
Physical data 
<br> Density 1.40&nbsp;g/cm&sup3; <br>
Melt. point 135&nbsp;&deg;C 
(275&nbsp;&deg;F) <br>
Boiling point 140&nbsp;&deg;C (284&nbsp;&deg;F) 
(decomposes) <br>
Solubility in water 3&nbsp;mg/mL (20&nbsp;&deg;C) <br>
&nbsp;Y
(what is this?)&nbsp;&nbsp;(verify)<br>
<br>
<br>

<p><b>Aspirin</b> (USAN), also known as <b>acetylsalicylic acid</b> (/&#601;
&#716;s&#603;t&#601;l&#716;s&aelig;l&#616;&#712;s&#618;l&#616;k/ <i>&#601;-<b>
set</b>-&#601;l-sal-i-<b>sil</b>-ik</i>; abbreviated <b>ASA</b>), is a 
salicylate drug, often used as an analgesic to relieve minor aches and pains, 
as anantipyretic to reduce fever, and as an anti-inflammatory medication. It 
was first isolated by Arthur Eichengr&uuml;n, a chemist with the German company
Bayer.[1]</p> 
<p>Salicylic acid, the main metabolite of aspirin, is an integral part of 
human and animal metabolism. While much of it is attributable to diet, a 
substantial part is synthesizedendogenously.[2]</p> 
<p>Aspirin also has an antiplatelet effect by inhibiting the production of 
thromboxane, which under normal circumstances binds platelet molecules together 
to create a patch over damaged walls of blood vessels. Because the platelet 
patch can become too large and also block blood flow, locally and downstream, 
aspirin is also used long-term, at low doses, to help preventheart attacks, 
strokes, and blood clot formation in people at high risk of developing blood 
clots.[3] It has also been established that low doses of aspirin may be given 
immediately after a heart attack to reduce the risk of another heart attack or 
of the death of cardiac tissue.[4][5]</p> 
<p>The main undesirable side-effects of aspirin taken by mouth are 
gastrointestinal ulcers, stomach bleeding, and tinnitus, especially in higher 
doses. In children and adolescents, aspirin is no longer indicated to control
flu-like symptoms or the symptoms of chickenpox or other viral illnesses, 
because of the risk ofReye's syndrome.[6]</p> 
<p>Aspirin is part of a group of medications called nonsteroidal 
anti-inflammatory drugs (NSAIDs), but differs from them in the mechanism of 
action. Though it, and others in its group called the salicylates, have similar 
effects (antipyretic, anti-inflammatory, analgesic) to the other NSAIDs and 
inhibit the same enzymecyclooxygenase, aspirin (but not the other salicylates) 
does so in an irreversible manner and, unlike others, affect more the COX-1 
variant than the COX-2 variant of the enzyme.[7] For example, NSAIDs' 
antiplatelet effects normally last in the order of hours, whereas aspirin's 
effects last for days (until the body replaces the suppressed platelets). 
Hence, when physicians tell patients to stop taking NSAIDs, they usually imply 
aspirin as well.</p> 
<p>Today, aspirin is one of the most widely used medications in the world, 
with an estimated 40,000tonnes of it being consumed each year.[8] In countries 
where<i>Aspirin</i> is a registered trademark owned by Bayer, the generic term 
is<i>acetylsalicylic acid</i> (ASA).[9]</p> 
<h2>Contents</h2> 
<ul> 
<li>1 Medical uses 
<ul> 
<li>1.1 Pain</li> 
<li>1.2 Headache</li> 
<li>1.3 Prevention of heart attacks and strokes</li> 
<li>1.4 Coronary and carotid arteries, bypasses and stents</li> 
<li>1.5 Other uses</li> 
<li>1.6 Experimental</li> 
<li>1.7 Resistance</li> 
<li>1.8 Dosage</li> </ul> </li> 
<li>2 Adverse effects 
<ul> 
<li>2.1 Contraindications</li> 
<li>2.2 Gastrointestinal</li> 
<li>2.3 Central effects</li> 
<li>2.4 Reye's syndrome</li> 
<li>2.5 Hives and swelling</li> 
<li>2.6 Other effects</li> 
<li>2.7 Overdose</li> 
<li>2.8 Interactions</li> </ul> </li> 
<li>3 Chemical properties 
<ul> 
<li>3.1 Synthesis</li> 
<li>3.2 Polymorphism</li> </ul> </li> 
<li>4 Mechanism of action 
<ul> 
<li>4.1 Discovery of the mechanism</li> 
<li>4.2 Suppression of prostaglandins and thromboxanes</li> 
<li>4.3 COX-1 and COX-2 inhibition</li> 
<li>4.4 Additional mechanisms</li> 
<li>4.5 Effects upon hypothalamic-pituitary-adrenal activity</li> </ul> </li> 
<li>5 Pharmacokinetics</li> 
<li>6 History 
<ul> 
<li>6.1 Trademark</li> </ul> </li> 
<li>7 Compendial status</li> 
<li>8 Veterinary use</li> 
<li>9 See also</li> 
<li>10 References</li> 
<li>11 External links</li> </ul> <br>
<br>

<h2>[edit] Medical uses</h2> 
<p>Aspirin is used for the treatment of a number of conditions including: fever
, pain,rheumatic fever, inflammatory diseases such as rheumatoid arthritis, 
pericarditis, and Kawasaki disease.[10] It is used in the prevention of 
transient ischemic attacks, strokes, heart attacks, pregnancy loss, and cancer.[
10]</p> 
<h3>[edit] Pain</h3> 
<p>In general, aspirin works well for dull, throbbing pain; it is ineffective 
for pain caused by most musclecramps, bloating, gastric distension, and acute 
skin irritation.[11] The most studied example is pain after surgery, such as 
tooth extraction, for which the highest allowed dose of aspirin (1 g) is 
equivalent to 1 g ofparacetamol (<b>acetaminophen</b>), 60&nbsp;mg of codeine, 
or 5&nbsp;mg ofoxycodone. A combination of aspirin and caffeine, in general, 
affords greater pain relief than aspirin alone. Effervescent aspirin alleviates 
pain much faster than aspirin in tablets (15&ndash;30 min vs. 45&ndash;60 min).[
12]</p> 
<p>Nevertheless, as a postsurgery painkiller, aspirin is inferior to ibuprofen 
and has higher gastrointestinal toxicity. The maximum dose of aspirin (1 g) 
provides weaker pain relief than an intermediate dose of ibuprofen 
(400&nbsp;mg), and this relief does not last as long.[12] A combination of 
aspirin and codeine may have a slightly higher analgesic effect than aspirin 
alone; however, this difference is not clinically meaningful.[13] It appears 
ibuprofen is at least equally, and possibly more, effective than this 
combination.[14]</p> 
<p>According to a 1998 meta-analysis of clinical trials for menstrual pain, 
aspirin demonstrated higher efficacy than placebo, but lower than ibuprofen or
naproxen, although maximum doses of aspirin were never used in these trials. 
The authors concluded ibuprofen has the best risk-benefit ratio.[15]</p> 
<p>Aspirin did not ease pain during cycling exercise,[16] while caffeine was 
very effective.[17][18] Likewise, aspirin, codeine, or paracetamol was not 
better than placebo for muscle soreness after exercise.[19]</p> 
<h3>[edit] Headache</h3> 
<p>Aspirin is a first-line drug in the treatment of migraine, bringing relief 
in 50&ndash;60% of the cases.[20] When used at a high dose of 1000&nbsp;mg (as 
compared to 275&ndash;325&nbsp;mg when used as a pain killer or 81&nbsp;mg as 
an antiplatelet therapy), no significant differences were seen as compared to
triptan medication, sumatriptan (Imitrex)[21] and other painkillers such as 
paracetamol (acetaminophen)[22] or ibuprofen.[23] The combination of aspirin, 
paracetamol (acetaminophen) andcaffeine (as found in the OTC brand Excedrin) is 
even more potent. For the treatment of migraine headache, this formulation 
works better than any of its three components taken separately,[22] better than 
ibuprofen[24] and better than sumatriptan. As with all other medications for 
migraine, it is recommended to take aspirin at the first signs of the headache, 
and it is the way these medications were used in the comparative clinical 
trials.[25]</p> 
<p>Aspirin alleviates pain in 60&ndash;75% of patients with episodic tension 
headaches.[26][27] It is equivalent to paracetamol (acetaminophen) in that 
respect, except for the higher frequency of gastrointestinal side-effects.[27] 
Comparative clinical trials indicatedmetamizole and ibuprofen may relieve pain 
faster than aspirin, although the difference becomes insignificant after about 
two hours. The addition of caffeine in a dose of 60&ndash;130&nbsp;mg to 
aspirin increases the analgesic effect in headache.[26][28] The combination of 
aspirin, paracetamol (acetaminophen) and caffeine is still more effective, but 
at the cost of more stomach discomfort, nervousness and dizziness.[29]</p> 
<p>There is some evidence low-dose aspirin has benefit for reducing the 
occurrence of migraines in susceptible individuals.[30][31][32][33]</p> 
<h3>[edit] Prevention of heart attacks and strokes</h3> 
<p>There are two distinct uses of aspirin for prophylaxis of cardiovascular 
events: primary prevention and secondary prevention. Primary prevention is 
about decreasingstrokes and heart attacks in the general population of those 
who have no diagnosed heart orvascular problems. Secondary prevention concerns 
patients with knowncardiovascular disease.[34]</p> 
<p>Low doses of aspirin are recommended for the secondary prevention of 
strokes and heart attacks. For both males and females diagnosed with 
cardiovascular disease, aspirin reduces the chance of a heart attack and
ischaemic stroke by about a fifth.[<i>citation needed</i>] This translates to 
an absolute rate reduction from 8.2% to 6.7% of such events per year for people 
already with cardiovascular disease.[<i>citation needed</i>] Although aspirin 
also raises the risk ofhemorrhagic stroke and other major bleeds by about 
twofold, these events are rare, and the balance of aspirin's effects is 
positive. Thus, in secondary prevention trials, aspirin reduced the overall 
mortality by about a tenth.[34]</p> 
<p>For persons without cardiovascular problems, the benefits of aspirin are 
unclear. In the primary prevention trials, aspirin decreased the overall 
incidence of heart attacks and ischaemic strokes by about a tenth. However, 
since these events were rare, the absolute reduction of their rate was low: 
from 0.57% to 0.51% per year. In addition, the risks of hemorrhagic strokes and 
gastrointestinal bleeding almost completely offset the benefits of aspirin. 
Thus, in the primary prevention trials, aspirin did not change the overall 
mortality rate.[34] Further trials are in progress[update].[34]</p> 
<p>The expert bodies diverge in their opinions regarding the use of aspirin 
for primary prevention, such as can be accomplished by including aspirin in a
polypill for the general population. The US Government Preventive Services Task 
Force recommended making individual, case by case choices based on the 
estimated future risk and patients' preferences.[35][36] On the other hand, 
Antithrombotic Trialists&rsquo; Collaboration argued such recommendations are 
unjustified, since the relative reduction of risk in the primary prevention 
trials of aspirin was same for persons in high- and low-risk groups and did not 
depend on the blood pressure. The Collaboration suggestedstatins as the 
alternative and more effective preventive medication.[34]</p> 
<h3>[edit] Coronary and carotid arteries, bypasses and stents</h3> 
<p>The coronary arteries supply blood to the heart. Aspirin is recommended for 
one to six months after placement ofstents in the coronary arteries and for 
years after acoronary artery bypass graft.</p> 
<p>The carotid arteries supply blood to the brain. Patients with mild carotid 
artery stenosis benefit from aspirin; it is recommended after a carotid 
endarterectomy or carotid artery stent.</p> 
<p>After vascular surgery of the lower legs using artificial grafts that are 
sutured to the arteries to improve blood supply, aspirin is used to keep the 
grafts open because it serves as type of blood thinner, reducing the likelihood 
of clots forming.</p> 
<h3>[edit] Other uses</h3> 
<p>Although aspirin has been used to combat fever and pains associated with 
common cold for more than 100 years, its efficacy in this role was only 
recently confirmed in controlled clinical trials on adults. One gram of 
aspirin, on average, reduced the oral body temperature from39.0 &deg;C 
(102.2&nbsp;&deg;F) to 37.6 &deg;C (99.7&nbsp;&deg;F) after three hours. The 
relief began after 30 minutes, and after six hours, the temperature still 
remained below37.8 &deg;C (100.0&nbsp;&deg;F). Aspirin also helped with 
&quot;achiness&quot;, discomfort, and headache,[37] and with sore throat pain, 
for those who had it.[38] The effects of aspirin were indistinguishable from 
those obtained using paracetamol in any respect, except for, possibly, a 
slightly higher incidence of sweating and gastrointestinal side-effects.[37]</p>
<p>Fever and joint pain of acute rheumatic fever respond extremely well, often 
within three days, to high doses of aspirin. The therapy usually lasts for one 
to two weeks; and only in about 5% of the cases it has to continue for longer 
than six months. After fever and pain have subsided, the aspirin treatment is 
unnecessary, as it does not decrease the incidence of heart complications and 
residual rheumatic heart disease.[39] In addition, the high doses of aspirin 
used caused liver toxicity in about 20% of the treated children,[40][41] who 
are the majority of rheumatic fever patients, and increased the risk of their 
developingReye's syndrome.[39] Naproxen was shown to be as effective as aspirin 
and less toxic; due to the limited clinical experience, however, naproxen is 
recommended only as a second-line treatment.[39][42]</p> 
<p>Along with rheumatic fever, Kawasaki disease remains one of the few 
indications for aspirin use in children, although even this use has been 
questioned by some researchers.[43] In the United Kingdom, the only indications 
for aspirin use in children and adolescents under 16 are Kawasaki disease and 
prevention of blood clot formation.</p> 
<p>Aspirin is also used in the treatment of pericarditis, coronary artery 
disease, and acute myocardial infarction.[44][45][46]</p> 
<p>Taking aspirin before air travel in cramped conditions has been suggested 
to decrease the risk ofdeep-vein thrombosis (DVT). The reason for taking 
aspirin is the long period of sitting without exercise, not air travel itself. 
A large, randomized, controlled trial in 2000 of aspirin against placebo in 
13,000 patients with hip fractures found &quot;a 29% relative risk reduction in 
DVT with 160 mg of aspirin taken daily for five weeks. Although there are 
obvious problems with extrapolating the data to long-distance travelers, this 
is the best evidence we could find to justify aspirin use&quot;.[47]</p> 
<h3>[edit] Experimental</h3> 
<p>Aspirin has been theorized to reduce cataract formation in diabetic 
patients, but one study showed it was ineffective for this purpose.[48] The 
role of aspirin in reducing the incidence of many forms ofcancer has also been 
widely studied. In several studies, its use did not reduce the incidence of
prostate cancer.[49][50] Its effects on the incidence of pancreatic cancer are 
mixed; one study published in 2004 found a statistically significant increase 
in the risk of pancreatic cancer among women,[51] while a meta-analysis of 
several studies, published in 2006, found no evidence aspirin or other NSAIDs 
are associated with an increased risk for the disease.[52] The drug may be 
effective in reduction of risk of various cancers, including those of thecolon,[
53][54][55][56][57] [58] lung,[59][60] and possibly the upper GI tract, though 
some evidence of its effectiveness in preventing cancer of the upper GI tract 
has been inconclusive.[61][61][62] Its preventative effect against 
adenocarcinomas may be explained by its inhibition of PTGS2 (COX-2) enzymes 
expressed in them.[63]</p> 
<p>A 2009 article published by the Journal of Clinical Investigation suggested 
that aspirin might prevent liver damage. In their experiment, scientists from
Yale University and The University of Iowa induced damage in certain liver 
cells (hepatocytes) using excessive doses of acetaminophen. This caused 
hepatoxicity and hepatocyte death, which triggered an increase in the 
production ofTLR9. The expression of TLR9 caused an inflammatory cascade 
involvingpro&ndash;IL-1&beta; and pro-IL-18. Aspirin was found to have a 
protective effect on hepatocytes because it led to the &quot;downregulation of 
proinflammatory cytokines&quot;.[64]</p> 
<p>In another 2009 article published by the Journal of the American Medical 
Association, men and women who regularly took aspirin after colorectal cancer 
diagnosis were found to have lower risks of overall and colorectal cancer death 
compared to patients not using aspirin.[65]</p> 
<p>A 2010 article in the Journal of Clinical Oncology has suggested aspirin 
may reduce the risk of death from breast cancer.[66] While the information has 
been well-circulated by the media,[67][68] official health bodies and medical 
groups have expressed concern over the touting of aspirin as a &quot;miracle 
drug&quot;.[69]</p> 
<p>A 2010 study by Oxford University involving over 25000 patients showed 
taking a small (75&nbsp;mg) daily dose of aspirin for between four and eight 
years substantially reduces death rates from a range of common cancers by at 
least a fifth and the reduction of risk continued for 20 years in both men and 
women. For specific cancers the, reduction was about 40% forbowel cancer, 30% 
forlung cancer, 10% for prostate cancer and 60% for oesophageal cancer, while 
the reductions inpancreas, stomach, brain, breast and ovarian cancers were 
difficult to quantify because there were not enough data, but other studies are 
in progress. However, taking aspirin doubles the annual risk of major internal 
bleeding that normally has a very low incidence (about 1 in 1000) in middle 
age, but increased dramatically after 75 years old.[70]</p> 
<h3>[edit] Resistance</h3> 
<p>For some people, aspirin does not have as strong an effect on platelets as 
for others, an effect known as aspirin resistance or insensitivity. One study 
has suggested women are more likely to be resistant than men,[71] and a 
different, aggregate study of 2,930 patients found 28% to be resistant.[72] A 
study in 100 Italian patients found that, of the apparent 31% aspirin-resistant 
subjects, only 5% were truly resistant, and the others werenoncompliant.[73]</p>
<h3>[edit] Dosage</h3> <br>
 Coated 325&nbsp;mg aspirin tablets 
<p>Adult aspirin tablets are produced in standardised sizes, which vary 
slightly from country to country, for example 300&nbsp;mg in Britain and 
325&nbsp;mg in the USA. Smaller doses are based on these standards; e.g. 75- 
and 81-milligram tablets are used; there is no medical significance in the 
slight difference. It is of historical interest that in the U.S., a 325&nbsp;mg 
dose is equivalent to the historic 5-grain aspirin tablet in use prior to the 
metric system.</p> 
<p>In general, for adults, doses are taken four times a day for fever or 
arthritis,[74] with doses near the maximal daily dose used historically for the 
treatment of rheumatic fever.[75] For the prevention of myocardial infarction 
in someone with documented or suspected coronary artery disease, much lower 
doses are taken once daily.[74]</p> 
<p>New recommendations from the US Preventive Services Task Force (USPSTF, 
March, 2009) on the use of aspirin for the primary prevention of coronary heart 
disease encourage men aged 45&ndash;79 and women aged 55&ndash;79 to use 
aspirin when the potential benefit of a reduction inmyocardial infarction (MI) 
for men or stroke for women outweighs the potential harm of an increase in 
gastrointestinal hemorrhage.[76] The WHI study said regular low dose (75 or 
81&nbsp;mg) aspirin female users had a 25% lower risk of death from 
cardiovascular disease and a 14% lower risk of death from any cause.[76] Low 
dose aspirin use was also associated with a trend toward lower risk of 
cardiovascular events, and lower aspirin doses (75 or 81&nbsp;mg/day) may 
optimize efficacy and safety for patients requiring aspirin for long-term 
prevention.[76]</p> 
<p>In children with Kawasaki disease, aspirin is taken at dosages based on 
body weight, initially four times a day for up to two weeks and then at a lower 
dose once daily for a further six to eight weeks.[77]</p> 
<h2>[edit] Adverse effects</h2> 
<h3>[edit] Contraindications</h3> 
<p>Aspirin should not be taken by people who are allergic to ibuprofen or 
naproxen,[78][79] or who have salicylate intolerance[80][81] or a more 
generalizeddrug intolerance to NSAIDs, and caution should be exercised in those 
withasthma or NSAID-precipitated bronchospasm. Owing to its effect on the 
stomach lining, manufacturers recommend people withpeptic ulcers, mild diabetes
, orgastritis seek medical advice before using aspirin.[78][82] Even if none of 
these conditions is present, there is still an increased risk ofstomach bleeding
 when aspirin is taken withalcohol or warfarin.[78][79] Patients with hemophilia
 or other bleeding tendencies should not take aspirin or other salicylates.[78][
82] Aspirin is known to cause hemolytic anemia in people who have the genetic 
diseaseglucose-6-phosphate dehydrogenase deficiency (G6PD), in particular in 
large doses and depending on the severity of the disease.[83] Use of aspirin 
duringdengue fever is not recommended owing to increased bleeding tendency.[84] 
People withkidney disease, hyperuricemia, or gout should not take aspirin 
because it inhibits the kidneys' ability to excreteuric acid, and thus may 
exacerbate these conditions. Aspirin should not be given to children or 
adolescents to control cold or influenza symptoms, as this has been linked with
Reye's syndrome.[6]</p> 
<h3>[edit] Gastrointestinal</h3> 
<p>Aspirin use has been shown to increase the risk of gastrointestinal bleeding
.[85] Although some enteric coated formulations of aspirin are advertised as 
being &quot;gentle to the stomach&quot;, in one study enteric coating did not 
seem to reduce this risk.[85] Combining aspirin with other NSAIDs has also been 
shown to further increase this risk.[85] Using aspirin in combination with 
clopidogrel or warfarin also increases the risk of upper gastrointestinal 
bleeding.[86]</p> 
<p>In addition to enteric coating, &quot;buffering&quot; is the other main 
method companies have used to try to mitigate the problem of gastrointestinal 
bleeding. Buffering agents are intended to work by preventing the aspirin from 
concentrating in the walls of the stomach, although the benefits of buffered 
aspirin are disputed. Almost any buffering agent used in antacids can be used; 
Bufferin, for example, uses MgO. Other preparations use CaCO3.[87]</p> 
<p>Taking it with vitamin C is a more recently investigated method of 
protecting the stomach lining. According to research done at a German 
university, taking equal doses of vitamin C and aspirin decreases the amount of 
stomach damage that occurs compared to taking aspirin alone.[88][89]</p> 
<p>It is reported that deglycyrrhizinated licorice (DGL), an extract of the 
popular herb licorice, helps relieve the symptoms of gastritis. In a 1979 
research study, a dose of 350 milligrams of DGL was shown to decrease the 
amount of gastrointestinal bleeding induced by three adult-strength aspirin 
tablets (750 milligrams).[90]</p> 
<p>A dose of 500 milligrams of S-adenosyl-methionine (SAMe, an amino acid 
naturally formed in the body) given together with a large dose of aspirin (1300 
milligrams) in a research study reduced the amount of stomach damage by 90 
percent.[91]</p> 
<p>A study found that, in contrast to oral aspirin, intravenous injection of 
aspirin did not produce detectable histological damage or significantly alter 
gastric mucosal potential difference, and concluded that high blood levels of 
circulating salicylate did not acutely damage gastric mucosa, so that gastric 
mucosal damage produced acutely after single oral doses of aspirin are due to 
itstopical, rather than systemic, action.[92]</p> 
<h3>[edit] Central effects</h3> 
<p>Large doses of salicylate, a metabolite of aspirin, have been proposed to 
causetinnitus (ringing in the ears) based on experiments in rats, via the 
action onarachidonic acid and NMDA receptors cascade.[93]</p> 
<h3>[edit] Reye's syndrome</h3>  Main article: Reye's syndrome <br>

<p>Reye's syndrome, a rare but severe illness characterized by acute 
encephalopathy and fatty liver, can occur when children or adolescents are 
given aspirin for a fever or other illnesses or infections. From 1981 through 
1997, 1207 cases of Reye's syndrome in under-18 patients were reported to the 
U.S.Centers for Disease Control and Prevention. Of these, 93% reported being 
ill in the three weeks preceding onset of Reye's syndrome, most commonly with a
respiratory infection, chickenpox, or diarrhea. Salicylates were detectable in 
81.9% of children for whom test results were reported.[94] After the 
association between Reye's syndrome and aspirin was reported and safety 
measures to prevent it (including aSurgeon General's warning and changes to the 
labeling of aspirin-containing drugs) were implemented, aspirin taken by 
children declined considerably in the United States, as did the number of 
reported cases of Reye's syndrome; a similar decline was found in the United 
Kingdom after warnings against pediatric aspirin use were issued.[94] The 
United StatesFood and Drug Administration now recommends aspirin (or 
aspirin-containing products) should not be given to anyone under the age of 12 
who has a fever,[6] and the British Medicines and Healthcare products 
Regulatory Agency (MHRA) recommends children who are under 16 years of age 
should not take aspirin, unless it is on the advice of a doctor.[95]</p> 
<h3>[edit] Hives and swelling</h3> 
<p>For a small number of people, taking aspirin can result in symptoms that 
resemble an allergic reaction, includinghives, swelling and headache. The 
reaction is caused bysalicylate intolerance and is not a true allergy, but 
rather an inability to metabolize even small amounts of aspirin, resulting in an
overdose.</p> 
<h3>[edit] Other effects</h3> 
<p>Aspirin can induce angioedema (swelling of skin tissues) in some people. In 
one study, angioedema appeared one to six hours after ingesting aspirin in some 
of the patients participating in the study. However, when the aspirin was taken 
alone, it did not cause angioedema in these patients; the aspirin had been 
taken in combination with another NSAID-induced drug when angioedema appeared.[
96]</p> 
<p>Aspirin causes an increased risk of cerebral microbleeds having the 
appearance onMRI scans of 5&ndash;10&nbsp;mm or smaller hypointense (dark 
holes) patches.[97][98] Such cerebral microbleeds are important since they 
often occur prior toischemic stroke or intracerebral hemorrhage, Binswanger 
disease and Alzheimer's disease.[<i>original research?</i>]</p> 
<p>A study of a group with a mean dosage of aspirin of 270 mg per day 
estimated that there was an average absolute risk increase inintracerebral 
hemorrhage (ICH) of 12 events per 10.000 persons.[99] In comparison, there was 
an estimated absolute risk reduction in myocardial infarction of 137 events per 
10.000 persons, and a reduction of 39 events per 10.000 persons in ischemic 
stroke.[99] In cases where ICH already has occurred, aspirin use results in 
higher mortality, with a dose of approximately 250 mg per day resulting in a
relative risk of death within three months after the ICH of approximately 2.5 
(95%confidence interval 1.3 to 4.6).[100]</p> 
<p>Aspirin and other NSAIDs can cause hyperkalemia by inducing a hyporenin 
hypoaldosteronic state via inhibition of prostaglandin synthesis; however, 
these agents do not typically causehyperkalemia by themselves in the setting of 
normal renal function and euvolemic state.[101]</p> 
<p>Aspirin can cause prolonged bleeding after operations for up to 10 days. In 
one study, 30 of 6499 elective surgical patients required reoperations to 
control bleeding. Twenty had diffuse bleeding and 10 had bleeding from a site. 
Diffuse, but not discrete, bleeding was associated with the preoperative use of 
aspirin alone or in combination with other NSAIDS in 19 of the 20 diffuse 
bleeding patients.[102]</p> This box: 
<ul> 
<li>view</li> 
<li>talk</li> 
<li>edit</li> </ul>  Laboratory findings in various platelet and coagulation 
disorders Condition Prothrombin time Partial thromboplastin time Bleeding time 
Platelet count <br>
Vitamin K deficiency or warfarin prolonged normal or mildly 
prolonged unaffected unaffected <br>
Disseminated intravascular coagulation 
prolonged prolonged prolonged decreased <br>
von Willebrand disease unaffected 
prolonged prolonged unaffected <br>
Hemophilia unaffected prolonged unaffected 
unaffected <br>
<strong>Aspirin</strong> unaffected unaffected prolonged 
unaffected <br>
Thrombocytopenia unaffected unaffected prolonged decreased <br>

Liver failure, early prolonged unaffected unaffected unaffected <br>
Liver 
failure, end-stage prolonged prolonged prolonged decreased <br>
Uremia 
unaffected unaffected prolonged unaffected <br>
Congenital afibrinogenemia 
prolonged prolonged prolonged unaffected <br>
Factor V deficiency prolonged 
prolonged unaffected unaffected <br>
Factor X deficiency as seen in amyloid 
purpura prolonged prolonged unaffected unaffected <br>
Glanzmann's 
thrombasthenia unaffected unaffected prolonged unaffected <br>
Bernard-Soulier 
syndrome unaffected unaffected prolonged decreased or unaffected <br>
<br>

<h3>[edit] Overdose</h3>  Main article: Aspirin poisoning <br>

<p>Aspirin overdose can be acute or chronic. In acute poisoning, a single 
large dose is taken; in chronic poisoning, higher than normal doses are taken 
over a period of time. Acute overdose has amortality rate of 2%. Chronic 
overdose is more commonly lethal, with a mortality rate of 25%;[<i>verification 
needed</i>] chronic overdose may be especially severe in children.[103] 
Toxicity is managed with a number of potential treatments, includingactivated 
charcoal, intravenous dextrose and normal saline, sodium bicarbonate, and 
dialysis.[104] The diagnosis of poisoning usually involves measurement of 
plasma salicylate, the active metabolite of aspirin, by automated 
spectrophotometric methods. Plasma salicylate levels in general range from 
30&ndash;100&nbsp;mg/L after usual therapeutic doses, 50&ndash;300&nbsp;mg/L in 
patients taking high doses and 700&ndash;1400&nbsp;mg/L following acute 
overdose. Salicylate is also produced as a result of exposure tobismuth 
subsalicylate, methyl salicylate and sodium salicylate.[105][106]</p> 
<h3>[edit] Interactions</h3> 
<p>Aspirin is known to interact with other drugs. For example, acetazolamide 
andammonium chloride have been known to enhance the intoxicating effect of 
salicyclates, andalcohol also increases the gastrointestinal bleeding 
associated with these types of drugs.[78][79] Aspirin is known to displace a 
number of drugs from protein binding sites in the blood, including the
antidiabetic drugs tolbutamide and chlorpropamide, the immunosuppressant 
methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with 
beta oxidation, an important part of valproate metabolism) and any nonsteroidal 
anti-inflammatory drug. Corticosteroids may also reduce the concentration of 
aspirin.Ibuprofen can negate the antiplatelet effect of aspirin used for 
cardioprotection and stroke prevention.[107] The pharmacological activity of 
spironolactone may be reduced by taking aspirin, and aspirin is known to 
compete withPenicillin G for renal tubular secretion.[108] Aspirin may also 
inhibit the absorption ofvitamin C.[109][110][111]</p> 
<h2>[edit] Chemical properties</h2> 
<p>Aspirin, an acetyl derivative of salicylic acid, is a white, crystalline, 
weakly acidic substance, with amelting point of 135 &deg;C (275&nbsp;&deg;F). 
Acetylsalicylic acid decomposes rapidly in solutions ofammonium acetate or of 
theacetatee, carbonates, citrates or hydroxides of the alkali metals. 
Acetylsalicylic acid is stable in dry air, but graduallyhydrolyses in contact 
with moisture to acetic and salicylicacids. In solution with alkalis, the 
hydrolysis proceeds rapidly and the clear solutions formed may consist entirely 
of acetate and salicylate.[112]</p> 
<h3>[edit] Synthesis</h3> 
<p>The synthesis of aspirin is classified as an esterification reaction. 
Salicylic acid is treated with acetic anhydride, an acid derivative, causing a 
chemical reaction that turns salicylic acid's hydroxyl group into an ester 
group (R-OH &rarr; R-OCOCH3). This process yields aspirin and acetic acid, 
which is considered abyproduct of this reaction. Small amounts of sulfuric acid 
(and occasionallyphosphoric acid) are almost always used as a catalyst. This 
method is commonly employed in undergraduate teaching labs.[113]</p> 
<dl> 
<dd> </dd> </dl> 
<dl> 
<dt> Reaction Mechanism </dt> 
<dd> </dd> </dl> 
<p>Formulations containing high concentrations of aspirin often smell like 
vinegar[114] because aspirin can decompose through hydrolysis in moist 
conditions, yielding salicylic acid andacetic acid.[115]</p> 
<p>The acid dissociation constant (pKa) for acetylsalicylic acid is 3.5 at 25 
&deg;C (77&nbsp;&deg;F).[116]</p> 
<h3>[edit] Polymorphism</h3> 
<p>Polymorphism, or the ability of a substance to form more than one crystal 
structure, is important in the development of pharmaceutical ingredients. Many 
drugs are receiving regulatory approval for only a single crystal form or 
polymorph. For a long time, only one crystal structure for aspirin was known, 
although there had been indications aspirin might have a second crystalline 
form since the 1960s. The elusive second polymorph was first discovered by 
Vishweshwar and coworkers in 2005,[117] and fine structural details were given 
by Bond et al.[118] A new crystal type was found after attempted 
cocrystallization of aspirin andlevetiracetam from hot acetonitrile. The form 
II is only stable at 100K and reverts to form I at ambient temperature. In the 
(unambiguous) form I, two salicylic molecules form centrosymmetricdimers 
through theacetyl groups with the (acidic) methyl proton to carbonyl hydrogen 
bonds, and in the newly claimed form II, each salicylic molecule forms the same 
hydrogen bonds with two neighboring molecules instead of one. With respect to 
the hydrogen bonds formed by thecarboxylic acid groups both polymorphs form 
identical dimer structures.</p> 
<h2>[edit] Mechanism of action</h2>  Main article: Mechanism of action of 
aspirin <br>

<h3>[edit] Discovery of the mechanism</h3> 
<p>In 1971, British pharmacologist John Robert Vane, then employed by the 
Royal College of Surgeons in London, showed aspirin suppressed the production of
prostaglandins and thromboxanes.[119][120] For this discovery, he was awarded 
both aNobel Prize in Physiology or Medicine in 1982 and a knighthood.</p> 
<h3>[edit] Suppression of prostaglandins and thromboxanes</h3> 
<p>Aspirin's ability to suppress the production of prostaglandins and 
thromboxanes is due to its irreversible inactivation of thecyclooxygenase 
(PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin 
acts as an acetylating agent where anacetyl group is covalently attached to a 
serine residue in the active site of the PTGS enzyme. This makes aspirin 
different from other NSAIDs (such asdiclofenac and ibuprofen), which are 
reversible inhibitors.</p> 
<p>Low-dose, long-term aspirin use irreversibly blocks the formation of 
thromboxane A2 in platelets, producing an inhibitory effect on platelet 
aggregation. This antithrombotic property makes aspirin useful for reducing the 
incidence of heart attacks.[121] 40&nbsp;mg of aspirin a day is able to inhibit 
a large proportion of maximum thromboxane A2 release provoked acutely, with the 
prostaglandin I2 synthesis being little affected; however, higher doses of 
aspirin are required to attain further inhibition.[122]</p> 
<p>Prostaglandins are local hormones produced in the body and have diverse 
effects, including the transmission of pain information to the brain, 
modulation of thehypothalamic thermostat, and inflammation. Thromboxanes are 
responsible for the aggregation of platelets that formblood clots. Heart 
attacks are caused primarily by blood clots, and low doses of aspirin are seen 
as an effective medical intervention for acutemyocardial infarction. An 
unwanted side-effect of the effective anticlotting action of aspirin is that it 
may cause excessive bleeding.</p> 
<h3>[edit] COX-1 and COX-2 inhibition</h3> 
<p>There are at least two different types of cyclooxygenase: COX-1 and COX-2. 
Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of 
COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. 
Aspirin-modified PTGS2 produces lipoxins, most of which are anti-inflammatory. 
Newer NSAID drugs,COX 2 inhibitors, have been developed to inhibit only PTGS2, 
with the intent to reduce the incidence of gastrointestinal side-effects.[8]</p>
<p>However, several of the new COX 2 inhibitors, such as rofecoxib (Vioxx), 
have been withdrawn recently, after evidence emerged that PTGS2 inhibitors 
increase the risk of heart attack. Endothelial cells lining the 
microvasculature in the body are proposed to express PTGS2, and, by selectively 
inhibiting PTGS2, prostaglandin production (to be specific, PGI2; prostacyclin) 
is downregulated with respect to thromboxane levels, as PTGS1 in platelets is 
unaffected. Thus, the protective anticoagulative effect ofPGI2 is removed, 
increasing the risk of thrombus and associated heart attacks and other 
circulatory problems. Since platelets have no DNA, they are unable to 
synthesize new PTGS once aspirin has irreversibly inhibited the enzyme, an 
important difference with reversible inhibitors.</p> 
<h3>[edit] Additional mechanisms</h3> 
<p>Aspirin has been shown to have at least three additional modes of action. 
It uncouplesoxidative phosphorylation in cartilaginous (and hepatic) 
mitochondria, by diffusing from the inner membrane space as a proton carrier 
back into the mitochondrial matrix, where it ionizes once again to release 
protons.[123] In short, aspirin buffers and transports the protons. When high 
doses of aspirin are given, it may actually cause fever, owing to the heat 
released from the electron transport chain, as opposed to the antipyretic 
action of aspirin seen with lower doses. In addition, aspirin induces the 
formation of NO-radicals in the body, which have been shown in mice to have an 
independent mechanism of reducing inflammation. This reduced leukocyte 
adhesion, which is an important step in immune response to infection; however, 
there is currently insufficient evidence to show that aspirin helps to fight 
infection.[124] More recent data also suggests that salicylic acid and its 
derivatives modulate signaling throughNF-&kappa;B.[125] NF-&kappa;B, a 
transcription factor complex, plays a central role in many biological 
processes, including inflammation.</p> 
<h3>[edit] Effects upon hypothalamic-pituitary-adrenal activity</h3> 
<p>Aspirin, like other medications affecting prostaglandin synthesis, has 
profound effects on thepituitary gland, which indirectly affects a number of 
other hormones and physiological functions. Effects ongrowth hormone, prolactin,
[126] and TSH (with relevant effect on T3 and T4) were observed directly.[127] 
Aspirin reduces the effects ofvasopressin[128] and increases those of naloxone[
129] upon the secretion of ACTH and cortisol by the 
hypothalamic-pituitary-adrenal axis (HPA axis), which has been suggested to 
occur through an interaction with endogenous prostaglandins and their role in 
regulating the HPA axis.[128]</p> 
<h2>[edit] Pharmacokinetics</h2> 
<p>Salicylic acid is a weak acid, and very little of it is ionized in the 
stomach after oral administration. Acetylsalicylic acid is poorly soluble in the
acidic conditions of the stomach, which can delay absorption of high doses for 
eight to 24 hours. The increased pH and larger surface area of thesmall 
intestine causes aspirin to be absorbed rapidly there, which in turn allows 
more of the salicylate to dissolve. Owing to the issue of solubility, however, 
aspirin is absorbed much more slowly during overdose, andplasma concentrations 
can continue to rise for up to 24 hours after ingestion.[130][131][132]</p> 
<p>About 50&ndash;80% of salicylate in the blood is bound by protein, while 
the rest remains in the active, ionized state; protein binding is 
concentration-dependent. Saturation of binding sites leads to more free 
salicylate and increased toxicity. The volume of distribution is 0.1&ndash;0.2 
l/kg. Acidosis increases the volume of distribution because of enhancement of 
tissue penetration of salicylates.[132]</p> 
<p>As much as 80% of therapeutic doses of salicylic acid is metabolized in the 
liver. Conjugation with glycine forms salicyluric acid, and with glucuronic acid
 it forms salicyl acyl and phenolic glucuronide. These metabolic pathways have 
only a limited capacity. Small amounts of salicylic acid are also hydroxylated 
togentisic acid. With large salicylate doses, the kinetics switch from first 
order to zero order, asmetabolic pathways become saturated and renal excretion 
becomes increasingly important.[132]</p> 
<p>Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), 
free salicylic acid (10%), salicylic phenol (10%), and acyl glucuronides (5%),
gentisic acid (&lt; 1%), and 2,3-dihydroxybenzoic acid.[133] When small doses 
(less than 250&nbsp;mg in an adult) are ingested, all pathways proceed by 
first-order kinetics, with an elimination half-life of about 2.0 to 4.5 hours.[
134][135] When higher doses of salicylate are ingested (more than 4 g), the 
half-life becomes much longer (15&ndash;30 hours),[136] because the 
biotransformation pathways concerned with the formation of salicyluric acid and 
salicyl phenolic glucuronide become saturated.[137] Renal excretion of 
salicylic acid becomes increasingly important as the metabolic pathways become 
saturated, because it is extremely sensitive to changes inurinary pH. There is 
a 10- to 20-fold increase in renal clearance when urine pH is increased from 5 
to 8. The use of urinary alkalinization exploits this particular aspect of 
salicylate elimination.[138]</p> 
<h2>[edit] History</h2>  Main article: History of aspirin <br>
<br>
 1923 
advertisement 
<p>Plant extracts, including willow bark and spiraea, of which salicylic acid 
was the active ingredient, had been known to help alleviate headaches, pains, 
and fevers since antiquity. The father of modern medicine,Hippocrates, who 
lived sometime between 460 BC and 377 BC, left historical records describing 
the use of powder made from the bark and leaves of the willow tree to help 
these symptoms.[139]</p> 
<p>A French chemist, Charles Frederic Gerhardt, was the first to prepare 
acetylsalicylic acid in 1853. In the course of his work on the synthesis and 
properties of variousacid anhydrides, he mixed acetyl chloride with a sodium 
salt of salicylic acid (sodium salicylate). A vigorous reaction ensued, and the 
resulting melt soon solidified.[140] Since no structural theory existed at that 
time, Gerhardt called the compound he obtained &quot;salicylic-acetic 
anhydride&quot; (<i>wasserfreie Salicyls&auml;ure-Essigs&auml;ure</i>). This 
preparation of aspirin (&quot;salicylic-acetic anhydride&quot;) was one of the 
many reactions Gerhardt conducted for his paper on anhydrides and he did not 
pursue it further.</p> <br>
 Advertisement for Aspirin, Heroin, Lycetol, and 
Salophen 
<p>Six years later, in 1859, von Gilm obtained analytically pure 
acetylsalicylic acid (which he called<i>acetylierte Salicyls&auml;ure</i>, 
acetylated salicylic acid) by a reaction of salicylic acid and acetyl chloride.[
141] In 1869, Schr&ouml;der, Prinzhorn and Kraut repeated both Gerhardt's (from 
sodium salicylate) and von Gilm's (from salicylic acid) syntheses and concluded 
both reactions gave the same compound&mdash;acetylsalicylic acid. They were 
first to assign to it the correct structure with the acetyl group connected to 
the phenolic oxygen.[142]</p> 
<p>In 1897, chemists working at Bayer AG produced a synthetically altered 
version ofsalicin, derived from the species meadowsweet (filipendula ulmaria), 
which caused less digestive upset than puresalicylic acid. The identity of the 
lead chemist on this project is a matter of controversy. Bayer's states that 
the work was done byFelix Hoffmann, but the Jewish chemist Arthur 
Eichengr&uuml;n later claimed he was the lead investigator and records of his 
contribution were expunged under theNazi regime.[143][144] The new drug, 
formally acetylsalicylic acid, was named Aspirin byBayer AG after the old 
botanical name for meadowsweet, <i>Spiraea ulmaria</i>. By 1899, Bayer was 
selling it around the world.[145] The name Aspirin is derived from <i>acetyl</i>
 and<i>spirs&auml;ure</i>, an old German name for salicylic acid.[146] The 
popularity of aspirin grew over the first half of the 20th century, spurred by 
its supposed effectiveness in the wake of theSpanish flu pandemic of 1918. 
However, recent research suggests the high death toll of the 1918 flu was 
partly due to aspirin, as the doses used at times can lead to toxicity, fluid 
in the lungs, and, in some cases, contribute to secondary bacterial infections 
and mortality.[147] Aspirin's profitability led to fierce competition and the 
proliferation of aspirin brands and products, especially after the American 
patent held by Bayer expired in 1917.[148][149]</p> 
<p>The popularity of aspirin declined after the market releases of paracetamol 
(acetaminophen) in 1956 andibuprofen in 1969.[150] In the 1960s and 1970s, John 
Vane and others discovered the basic mechanism of aspirin's effects, while 
clinical trials and other studies from the 1960s to the 1980s established 
aspirin's efficacy as an anticlotting agent that reduces the risk of clotting 
diseases.[151] Aspirin sales revived considerably in the last decades of the 
20th century, and remain strong in the 21st century, because of its widespread 
use as a preventive treatment forheart attacks and strokes.[152]</p> 
<h3>[edit] Trademark</h3> 
<p>As part of war reparations specified in the 1919 Treaty of Versailles 
following Germany's surrender afterWorld War I, Aspirin (along with heroin) 
lost its status as a registered trademark inFrance, Russia, the United Kingdom, 
and theUnited States, where it became a generic name.[153][154][155] Today, 
&quot;aspirin&quot; is a generic word in Australia, France, India, Ireland, New 
Zealand,Pakistan, Jamaica, Colombia, the Philippines, South Africa, United 
Kingdom and the United States.[156] Aspirin, with a capital &quot;A&quot;, 
remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 
80 other countries, where the trademark is owned byBayer, using acetylsalicylic 
acid in all markets, but using different packaging and physical aspects for 
each.[157][158]</p> 
<h2>[edit] Compendial status</h2> 
<ul> 
<li>United States Pharmacopeia [159][<i>clarification needed</i>]</li> 
<li>British Pharmacopoeia [160]</li> </ul> 
<h2>[edit] Veterinary use</h2> 
<p>Aspirin is sometimes used for pain relief or as an anti-coagulant in 
veterinary medicine, primarily indogs and sometimes horses, although newer 
medications with fewer side-effects are generally used instead. Both dogs and 
horses are susceptible to the gastrointestinal side-effects associated with 
salicylates, but it is a convenient treatment for arthritis in older dogs and 
has shown some promise in cases oflaminitis in horses.[161][162] Aspirin should 
be used in animals only under the direct supervision of aveterinarian; in 
particular,cats lack the glucuronide conjugates that aid in the excretion of 
aspirin, making even low doses potentially toxic.[163]</p> 
<h2>[edit] See also</h2> 
<ul> 
<li>Aspirin poisoning</li> 
<li>History of aspirin</li> 
<li>NSAID</li> </ul> 
<h2>[edit] References</h2> 
<ol> 
<li><b>^</b> Sneader, W. (2000). &quot;The discovery of aspirin: A 
reappraisal&quot;. <i>BMJ (Clinical research ed.)</i> <b>321</b> (7276): 
1591&ndash;1594.doi:10.1136/bmj.321.7276.1591. PMC&nbsp;1119266. PMID&nbsp;
11124191. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1119266
.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Paterson, John R.; Baxter, Gwendoline; Dreyer, Jacob S.; Halket, 
John M.; Flynn, Robert; Lawrence, James R. (2008).&quot;Salicylic Acid sans 
Aspirin in Animals and Man: Persistence in Fasting and Biosynthesis from 
Benzoic Acid&quot;. <i>Journal of Agricultural and Food Chemistry</i> <b>56</b> 
(24): 11648&ndash;11652.doi:10.1021/jf800974z. PMC&nbsp;2800778. PMID&nbsp;
19053387. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2800778
.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Lewis, H D; J W Davis, D G Archibald, W E Steinke, T C 
Smitherman, J E Doherty, H W Schnaper, M M LeWinter, E Linares, J M Pouget, S C 
Sabharwal, E Chesler, H DeMots (1983-08-18). &quot;Protective effects of 
aspirin against acute myocardial infarction and death in men with unstable 
angina. Results of a Veterans Administration Cooperative Study&quot;.<i>The New 
England journal of medicine</i> <b>309</b> (7): 396&ndash;403. doi:
10.1056/NEJM198308183090703. ISSN&nbsp;00284793. PMID&nbsp;6135989.&nbsp;</li> 
<li><b>^</b> Julian, D G; D A Chamberlain, S J Pocock (1996-09-24). &quot;A 
comparison of aspirin and anticoagulation following thrombolysis for myocardial 
infarction (the AFTER study): a multicentre unblinded randomised clinical 
trial&quot;. <i>BMJ</i> (British Medical Journal) <b>313</b> (7070): 
1429&ndash;1431.PMC&nbsp;2353012. PMID&nbsp;8973228. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2353012
.&nbsp;</li> 
<li><b>^</b> Krumholz, Harlan M.; Martha J. Radford, Edward F. Ellerbeck, John 
Hennen, Thomas P. Meehan, Marcia Petrillo, Yun Wang, Timothy F. Kresowik, 
Stephen F. Jencks (1995). &quot;Aspirin in the Treatment of Acute Myocardial 
Infarction in Elderly Medicare Beneficiaries&nbsp;: Patterns of Use and 
Outcomes&quot;.<i>Circulation</i> <b>92</b> (10): 2841&ndash;2847. PMID&nbsp;
7586250.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> Macdonald S (2002). 
&quot;Aspirin use to be banned in under 16 year olds&quot;. <i>BMJ</i> <b>325
</b> (7371): 988. doi:10.1136/bmj.325.7371.988/c. PMC&nbsp;1169585. PMID&nbsp;
12411346. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1169585
.&nbsp;</li> 
<li><b>^</b> Burke, Anne; Smyth, Emer; FitzGerald, Garret A. (2006). <i>
Chapter 26: Analgesic Antipyretic and Antiinflammatory Agents in Goodman and 
Gilman's the pharmacological basis of therpeutics.</i>. New York: McGraw-Hill. 
pp.&nbsp;671&ndash;716.ISBN&nbsp;0071422803. 
http://www.accessmedicine.com/content.aspx?aID=942410&amp;searchStr=aspirin.
&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Warner, T. D.; Warner TD, Mitchell JA. 
(2002).&quot;Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX 
continuum?&quot;. <i>Proc Natl Acad Sci USA</i> <b>99</b> (21): 13371&ndash;3. 
doi:10.1073/pnas.222543099. PMC&nbsp;129677. PMID&nbsp;12374850. 
http://www.pnas.org/cgi/content/extract/99/21/13371.&nbsp;</li> 
<li><b>^</b> &quot;The use of aspirin&quot;. Wordconstructions.com. 
http://www.wordconstructions.com/articles/health/aspirin.html. Retrieved 
2011-05-11.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> &quot;Aspirin&quot;. <i>The American 
Society of Health-System Pharmacists</i>. 
http://www.drugs.com/monograph/aspirin.html. Retrieved 3 April 2011.&nbsp;</li> 
<li><b>^</b> Gaciong (2003). &quot;The real dimension of analgesic activity of 
aspirin&quot;.<i>Thrombosis research</i> <b>110</b> (5&ndash;6): 361&ndash;364. 
doi:10.1016/j.thromres.2003.08.009. PMID&nbsp;14592563.&nbsp;&nbsp;edit</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Hersh, E.; Moore, P.; Ross, G. (2000). 
&quot;Over-the-counter analgesics and antipyretics: A critical assessment&quot;.
<i>Clinical Therapeutics</i> <b>22</b> (5): 500&ndash;548. doi:
10.1016/S0149-2918(00)80043-0. PMID&nbsp;10868553.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Zhang; Po, A. L. (1997). &quot;Do codeine and caffeine enhance 
the analgesic effect of aspirin?--A systematic overview&quot;.<i>Journal of 
clinical pharmacy and therapeutics</i> <b>22</b> (2): 79&ndash;97. doi:
10.1111/j.1365-2710.1997.tb00002.x. PMID&nbsp;9373807.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Cooper; Engel, J.; Ladov, M.; Precheur, H.; Rosenheck, A.; Rauch, 
D. (1982). &quot;Analgesic efficacy of an ibuprofen-codeine combination&quot;.
<i>Pharmacotherapy</i> <b>2</b> (3): 162&ndash;167. PMID&nbsp;6763202.&nbsp;
&nbsp;edit</li> 
<li><b>^</b> Zhang; Li Wan Po, A. (1998). &quot;Efficacy of minor analgesics 
in primary dysmenorrhoea: a systematic review&quot;.<i>British journal of 
obstetrics and gynaecology</i> <b>105</b> (7): 780&ndash;789. doi:
10.1111/j.1471-0528.1998.tb10210.x. PMID&nbsp;9692420.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Cook; O'Connor, P. J.; Eubanks, S. A.; Smith, J. C.; Lee, M. 
(1997). &quot;Naturally occurring muscle pain during exercise: assessment and 
experimental evidence&quot;.<i>Medicine and science in sports and exercise</i> 
<b>29</b> (8): 999&ndash;1012. doi:10.1097/00005768-199708000-00004. PMID&nbsp;
9268956.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Gliottoni; Motl, R. W. (2008). &quot;Effect of caffeine on 
leg-muscle pain during intense cycling exercise: possible role of anxiety 
sensitivity&quot;.<i>International journal of sport nutrition and exercise 
metabolism</i> <b>18</b> (2): 103&ndash;115. PMID&nbsp;18458355.&nbsp;&nbsp;edit
</li> 
<li><b>^</b> Motl; O'Connor, P. J.; Dishman, R. K. (2003). &quot;Effect of 
caffeine on perceptions of leg muscle pain during moderate intensity cycling 
exercise&quot;.<i>The journal of pain&nbsp;: official journal of the American 
Pain Society</i> <b>4</b> (6): 316&ndash;321. doi:10.1016/S1526-5900(03)00635-7.
PMID&nbsp;14622688.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Barlas, P.; Craig, J.; Robinson, J.; Walsh, D.; Baxter, G.; 
Allen, J. (2000). &quot;Managing delayed-onset muscle soreness: Lack of effect 
of selected oral systemic analgesics&quot;.<i>Archives of Physical Medicine and 
Rehabilitation</i> <b>81</b> (7): 966&ndash;972. doi:10.1053/apmr.2000.6277. 
PMID&nbsp;10896014.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Tfelt-Hansen P (2008). &quot;Triptans vs Other Drugs for Acute 
Migraine. Are There Differences in Efficacy? A Comment&quot;.<i>Headache</i> <b>
48</b> (4): 601&ndash;605. doi:10.1111/j.1526-4610.2008.01064.x. PMID&nbsp;
18377382.&nbsp;</li> 
<li><b>^</b> Lampl C, Voelker M, Diener HC (2007). &quot;Efficacy and safety 
of 1,000 mg effervescent aspirin: individual patient data meta-analysis of 
three trials in migraine headache and migraine accompanying symptoms&quot;.<i>J 
Neurol</i> <b>254</b> (6): 705&ndash;712. doi:10.1007/s00415-007-0547-2. PMID
&nbsp;17406776.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Diener HC, Bussone G, de Liano H et al 
(2004). &quot;The fixed combination of acetylsalicylic acid, paracetamol and 
caffeine is more effective than single substances and dual combination for the 
treatment of headache: a multicentre, randomized, double-blind, single-dose, 
placebo-controlled parallel group study&quot;.<i>Cephalalgia</i> <b>25</b> 
(10): 776&ndash;787.doi:10.1111/j.1468-2982.2005.00948.x. PMID&nbsp;16162254.
&nbsp;</li> 
<li><b>^</b> Diener HC, Pfaffenrath V, Pageler L et al (2004). &quot;Efficacy 
and safety of 1,000 mg effervescent aspirin: individual patient data 
meta-analysis of three trials in migraine headache and migraine accompanying 
symptoms&quot;.<i>Cephalalgia</i> <b>24</b> (11): 947&ndash;54. doi:
10.1111/j.1468-2982.2004.00783.x. PMID&nbsp;15482357.&nbsp;</li> 
<li><b>^</b> Goldstein J, Silberstein SD, Saper JR et al (2006). 
&quot;Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for 
acute migraine: results from a multicenter, double-blind, randomized, 
parallel-group, single-dose, placebo-controlled study&quot;.<i>Headache</i> <b>
46</b> (3): 444&ndash;53. doi:10.1111/j.1526-4610.2006.00376.x. PMID&nbsp;
16618262.&nbsp;</li> 
<li><b>^</b> Goldstein J, Silberstein SD, Saper JR et al (2005). 
&quot;Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the 
early treatment of migraine: results from the ASSET trial&quot;.<i>Headache</i> 
<b>45</b> (8): 973&ndash;82. doi:10.1111/j.1526-4610.2005.05177.x. PMID&nbsp;
16109110.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Mart&iacute;nez-Mart&iacute;n, P.; 
Raffaelli E, E.; Titus, F.; Despuig, J.; Fragoso, Y. D.; D&iacute;ez-Tejedor, 
E.; Lia&ntilde;o, H.; Leira, R. et al (2001). &quot;Efficacy and safety of 
metamizol vs. Acetylsalicylic acid in patients with moderate episodic 
tension-type headache: a randomized, double-blind, placebo- and 
active-controlled, multicentre study&quot;.<i>Cephalalgia&nbsp;: an 
international journal of headache</i> <b>21</b> (5): 604&ndash;610. doi:
10.1046/j.1468-2982.2001.00216.x. PMID&nbsp;11472387.&nbsp;&nbsp;edit</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Steiner, T. J.; Lange, R.; Voelker, M. 
(2003). &quot;Aspirin in episodic tension-type headache: placebo-controlled 
dose-ranging comparison with paracetamol&quot;.<i>Cephalalgia&nbsp;: an 
international journal of headache</i> <b>23</b> (1): 59&ndash;66. doi:
10.1046/j.1468-2982.2003.00470.x. PMID&nbsp;12534583.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Nebe, J.; Heier, M.; Diener, H. C. (1995). &quot;Low-dose 
ibuprofen in self-medication of mild to moderate headache: a comparison with 
acetylsalicylic acid and placebo&quot;.<i>Cephalalgia&nbsp;: an international 
journal of headache</i> <b>15</b> (6): 531&ndash;535. doi:
10.1046/j.1468-2982.1995.1506531.x. PMID&nbsp;8706118.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Migliardi, J. R.; Armellino; Friedman; Gillings; Beaver (1994). 
&quot;Caffeine as an analgesic adjuvant in tension headache&quot;.<i>Clinical 
pharmacology and therapeutics</i> <b>56</b> (5): 576&ndash;586. doi:
10.1038/clpt.1994.179. PMID&nbsp;7955822.&nbsp;&nbsp;edit</li> 
<li><b>^</b> &quot;Aspirin and Migraine&quot;. National Headache Foundation. 
http://www.headaches.org/education/Medications/Aspirin_and_Migraine. Retrieved 
2011-03-28.&nbsp;</li> 
<li><b>^</b> K.A. Fackelmann (1990-02-17). &quot;Low dose of aspirin keeps 
migraine away&quot;. Science News. 
http://findarticles.com/p/articles/mi_m1200/is_n7_v137/ai_8556715/. Retrieved 
2011-03-28.&nbsp;</li> 
<li><b>^</b> Dalessio. D.J. (1990-02-17). &quot;Aspirin prophylaxis for 
migraine&quot;. ISSN&nbsp;0098-7484. 
http://www.faqs.org/abstracts/Health/Aspirin-prophylaxis-for-migraine-A-meta-analysis-of-low-dose-aspirin-for-the-prevention-of-pregnancy.html
. Retrieved 2011-03-28.&nbsp;</li> 
<li><b>^</b> Hennekens, Charles H., Buring, Julie E., Peto, Richard (1990). 
&quot;Low-dose aspirin for migraine prophylaxis&quot;. JAMA, The Journal of the 
American Medical Association.ISSN&nbsp;0098-7484. 
http://www.ncbi.nlm.nih.gov/pubmed/2204739. Retrieved 2011-03-28.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> <i><b>d</b></i> <i><b>e
</b></i> Baigent C, Blackwell L, Collins R, <i>et al.</i> (2009). &quot;Aspirin 
in the primary and secondary prevention of vascular disease: collaborative 
meta-analysis of individual participant data from randomised trials&quot;. <i>
Lancet</i> <b>373</b> (9678): 1849&ndash;60. doi:10.1016/S0140-6736(09)60503-1. 
PMC&nbsp;2715005. PMID&nbsp;19482214. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2715005
.&nbsp;</li> 
<li><b>^</b> Wolff T, Miller T, Ko S (2009). &quot;Aspirin for the primary 
prevention of cardiovascular events: an update of the evidence for the U.S. 
Preventive Services Task Force&quot;.<i>Ann. Intern. Med.</i> <b>150</b> (6): 
405&ndash;10.PMID&nbsp;19293073.&nbsp;</li> 
<li><b>^</b> US Preventive Services Task Force (2009). &quot;Aspirin for the 
prevention of cardiovascular disease: U.S. Preventive Services Task Force 
recommendation statement&quot;.<i>Ann. Intern. Med.</i> <b>150</b> (6): 
396&ndash;404.PMID&nbsp;19293072.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Bachert, C.; Chuchalin, A.; Eisebitt, 
R.; Netayzhenko, V.; Voelker, M. (2005). &quot;Aspirin compared with 
acetaminophen in the treatment of fever and other symptoms of upper respiratory 
tract infection in adults: a multicenter, randomized, double-blind, 
double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour 
dose-ranging study&quot;.<i>Clinical therapeutics</i> <b>27</b> (7): 
993&ndash;1003.doi:10.1016/j.clinthera.2005.06.002. PMID&nbsp;16154478.&nbsp;
&nbsp;edit</li> 
<li><b>^</b> Eccles, R.; Loose, I.; Jawad, M.; Nyman, L. (2003). &quot;Effects 
of acetylsalicylic acid on sore throat pain and other pain symptoms associated 
with acute upper respiratory tract infection&quot;.<i>Pain medicine (Malden, 
Mass.)</i> <b>4</b> (2): 118&ndash;124. doi:10.1046/j.1526-4637.2003.03019.x. 
PMID&nbsp;12873261.&nbsp;&nbsp;edit</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> National Heart 
Foundation of Australia (RF/RHD guideline development working group) and the 
Cardiac Society of Australia and New Zealand (2006).&quot;Diagnosis and 
management of acute rheumatic fever and rheumatic heart disease in Australia. 
An evidence-based review&quot; (PDF). National Heart Foundation of Australia. 
pp. 33&ndash;37. 
http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/DiagnosisandmanagementofacuterheumaticfeverandrheumaticheartdiseaseinAustralia/NHFA-CSANZ_ARF_RHD_2006.pdf
. Retrieved 2011-05-09.&nbsp;</li> 
<li><b>^</b> Karademir; O&#287;uz, D.; Senocak, F.; Ocal, B.; Karakurt, C.; 
Cabuk, F. (2003). &quot;Tolmetin and salicylate therapy in acute rheumatic 
fever: Comparison of clinical efficacy and side-effects&quot;.<i>Pediatrics 
international&nbsp;: official journal of the Japan Pediatric Society</i> <b>45
</b> (6): 676&ndash;679. PMID&nbsp;14651540.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Singh; Chugh, J. C.; Shembesh, A. H.; Ben-Musa, A. A.; Mehta, H. 
C. (1992). &quot;Hepatotoxicity of high dose salicylate therapy in acute 
rheumatic fever&quot;.<i>Annals of tropical paediatrics</i> <b>12</b> (1): 
37&ndash;40.PMID&nbsp;1376585.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Hashkes; Tauber, T.; Somekh, E.; Brik, R.; Barash, J.; Mukamel, 
M.; Harel, L.; Lorber, A. et al (2003). &quot;Naproxen as an alternative to 
aspirin for the treatment of arthritis of rheumatic fever: a randomized 
trial&quot;.<i>The Journal of pediatrics</i> <b>143</b> (3): 399&ndash;401. doi:
10.1067/S0022-3476(03)00388-3. PMID&nbsp;14517527.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM (2004). 
&quot;Treatment of acute Kawasaki disease: aspirin's role in the febrile stage 
revisited&quot;. <i>Pediatrics</i> <b>114</b> (6): e689&ndash;93. doi:
10.1542/peds.2004-1037. PMID&nbsp;15545617. 
http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&amp;pmid=15545617
.&nbsp;</li> 
<li><b>^</b> Krumholz, HM; Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, 
Petrillo M, Wang Y, Kresowik TF, Jencks SF. (1995). &quot;Aspirin in the 
treatment of acute myocardial infarction in elderly Medicare beneficiaries. 
Patterns of use and outcomes&quot;.<i>Circulation</i> <b>92</b> (10): 
2841&ndash;7.PMID&nbsp;7586250.&nbsp;</li> 
<li><b>^</b> ISIS-2 Collaborative group (1988). &quot;Randomized trial of 
intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of 
suspected acute myocardial infarction: ISIS-2&quot;.<i>Lancet</i> <b>2</b> (2): 
349&ndash;60.PMID&nbsp;2899772.&nbsp;</li> 
<li><b>^</b> Mallinson, T (2010). &quot;Myocardial Infarction&quot;. <i>Focus 
on First Aid</i> (15): 15. 
http://www.focusonfirstaid.co.uk/Magazine/issue15/index.aspx. Retrieved 
2010-06-08.&nbsp;</li> 
<li><b>^</b> &quot;Loke and Dery: Air Travel and Venous Thrombosis: How Much 
Help Might Aspirin Be? 2002&quot;. Medscape.com. 
http://www.medscape.com/viewarticle/441153. Retrieved 2011-05-11.&nbsp;</li> 
<li><b>^</b> Chew EY, Williams GA, Burton TC, Barton FB, Remaley NA, Ferris FL 
(1992). &quot;Aspirin effects on the development of cataracts in patients with 
diabetes mellitus. Early treatment diabetic retinopathy study report 16&quot;.
<i>Arch Ophthalmol</i> <b>110</b> (3): 339&ndash;42. PMID&nbsp;1543449.&nbsp;
</li> 
<li><b>^</b> Bosetti, <i>et al.</i>; Talamini, R; Negri, E; Franceschi, S; 
Montella, M; La Vecchia, C (2006). &quot;Aspirin and the risk of prostate 
cancer&quot;.<i>Eur J Cancer Prev</i> <b>15</b> (1): 43&ndash;5. doi:
10.1097/01.cej.0000180665.04335.de. PMID&nbsp;16374228.&nbsp;</li> 
<li><b>^</b> Menezes, <i>et al.</i>; Swede, H; Niles, R; Moysich, KB (2006). 
&quot;Regular use of aspirin and prostate cancer risk (United States)&quot;.<i>
Cancer Causes &amp; Control</i> <b>17</b> (3): 251&ndash;6. doi:
10.1007/s10552-005-0450-z. PMID&nbsp;16489532.&nbsp;</li> 
<li><b>^</b> Schernhammer, <i>et al.</i>; Kang, JH; Chan, AT; Michaud, DS; 
Skinner, HG; Giovannucci, E; Colditz, GA; Fuchs, CS (2004).&quot;A Prospective 
Study of Aspirin Use and the Risk of Pancreatic Cancer in Women&quot;. <i>J 
Natl Cancer Inst</i> <b>96</b> (1): 22&ndash;28. doi:10.1093/jnci/djh001. PMID
&nbsp;14709735. http://jnci.oxfordjournals.org/cgi/content/full/96/1/22.&nbsp;
</li> 
<li><b>^</b> Larsson SC, Giovannucci E, Bergkvist L, Wolk A (2006). 
&quot;Aspirin and nonsteroidal anti-inflammatory drug use and risk of 
pancreatic cancer: a meta-analysis&quot;. <i>Cancer Epidemiol. Biomarkers Prev.
</i> <b>15</b> (12): 2561&ndash;4. doi:10.1158/1055-9965.EPI-06-0574. PMID&nbsp;
17164387. http://cebp.aacrjournals.org/cgi/content/full/15/12/2561.&nbsp;</li> 
<li><b>^</b> Thun MJ, Namboodiri MM, Heath CW (1991). &quot;Aspirin use and 
reduced risk of fatal colon cancer&quot;.<i>N Engl J Med</i> <b>325</b> (23): 
1593&ndash;6.doi:10.1056/NEJM199112053252301. PMID&nbsp;1669840.&nbsp;</li> 
<li><b>^</b> Baron, <i>et al.</i>; Cole, BF; Sandler, RS; Haile, RW; Ahnen, D; 
Bresalier, R; McKeown-Eyssen, G; Summers, RW et al (2003). &quot;A randomized 
trial of aspirin to prevent colorectal adenomas&quot;.<i>N Engl J Med</i> <b>348
</b> (10): 891&ndash;9. doi:10.1056/NEJMoa021735. PMID&nbsp;12621133.&nbsp;</li>
<li><b>^</b> Chan, <i>et al.</i>; Giovannucci, EL; Schernhammer, ES; Colditz, 
GA; Hunter, DJ; Willett, WC; Fuchs, CS (2004). &quot;A Prospective Study of 
Aspirin Use and the Risk for Colorectal Adenoma&quot;.<i>Ann Intern Med</i> <b>
140</b> (3): 157&ndash;66. PMID&nbsp;14757613.&nbsp;</li> 
<li><b>^</b> Chan, <i>et al.</i>; Giovannucci, EL; Meyerhardt, JA; 
Schernhammer, ES; Curhan, GC; Fuchs, CS (2005).&quot;Long-term Use of Aspirin 
and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer&quot;. 
<i>JAMA</i> <b>294</b> (8): 914&ndash;23. doi:10.1001/jama.294.8.914. PMC&nbsp;
1550973. PMID&nbsp;16118381. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1550973
.&nbsp;</li> 
<li><b>^</b> Prof Peter M Rothwell FMedSci, Michelle Wilson BSc, Carl-Eric 
Elwin MD, Prof Bo Norrving PhD, Prof Ale Algra MD, Prof Charles P Warlow 
FMedSci, Prof Tom W Meade FRS (2010). &quot;Long-term effect of aspirin on 
colorectal cancer incidence and mortality: 20-year follow-up of five randomised 
trials&quot;.<i>The Lancet</i> <b>376</b> (9754): 1741&ndash;1750. doi:
10.1016/S0140-6736(10)61543-7.&nbsp;</li> 
<li><b>^</b> &quot;Aspirin may help fight colon cancer - USATODAY.com&quot;. 
Yourlife.usatoday.com. 
http://yourlife.usatoday.com/health/story/2011-10-27/Aspirin-reduces-colon-cancer-risk-by-60/50963272/1
. Retrieved 2011-11-09.&nbsp;</li> 
<li><b>^</b> Akhmedkhanov, <i>et al.</i>; Toniolo, P; Zeleniuch-Jacquotte, A; 
Koenig, KL; Shore, RE (2002).&quot;Aspirin and lung cancer in women&quot;. <i>
Br J cancer</i> <b>87</b> (11): 1337&ndash;8. doi:10.1038/sj.bjc.6600370. PMC
&nbsp;2364276. PMID&nbsp;12085255. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2364276
.&nbsp;</li> 
<li><b>^</b> Moysich KB, Menezes RJ, Ronsani A, <i>et al.</i> (2002). 
&quot;Regular aspirin use and lung cancer risk&quot;. <i>BMC Cancer</i> <b>2</b>
: 31.doi:10.1186/1471-2407-2-31. PMC&nbsp;138809. PMID&nbsp;12453317. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=138809
.&nbsp; Free full text</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Jayaprakash, Vijayvel; Jayaprakash V, 
Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. 
(2006). &quot;Regular aspirin use and esophageal cancer risk&quot;.<i>Int J 
Cancer</i> <b>119</b> (1): 202&ndash;7. doi:10.1002/ijc.21814. PMID&nbsp;
16450404.&nbsp;</li> 
<li><b>^</b> Bosetti, <i>et al.</i>; Talamini, R; Franceschi, S; Negri, E; 
Garavello, W; La Vecchia, C (2003).&quot;Aspirin use and cancers of the upper 
aerodigestive tract&quot;. <i>Br J Cancer</i> <b>88</b> (5): 672&ndash;74. doi:
10.1038/sj.bjc.6600820. PMC&nbsp;2376339. PMID&nbsp;12618872. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2376339
.&nbsp;</li> 
<li><b>^</b> Wolff, <i>et al.</i>; Saukkonen, K; Anttila, S; Karjalainen, A; 
Vainio, H; Ristim&auml;ki, A (15 November 1998).&quot;Expression of 
cyclooxygenase-2 in human lung carcinoma&quot;. <i>Cancer Research</i> <b>58</b>
 (22): 4997&ndash;5001.PMID&nbsp;9823297. 
http://cancerres.aacrjournals.org/cgi/content/abstract/58/22/4997.&nbsp;</li> 
<li><b>^</b> Imaeda, Avlin B.; Watanabe, Azuma; Sohail, Muhammad A.; Mahmood, 
Shamail; Mohamadnejad, Mehdi; Sutterwala, Fayyaz S.; Flavell, Richard A.; 
Mehal, Wajahat Z. (2009).&quot;Acetaminophen-induced hepatotoxicity in mice is 
dependent on Tlr9 and the Nalp3 inflammasome&quot;. <i>Journal of Clinical 
Investigation</i> <b>119</b> (2): 305&ndash;14. doi:10.1172/JCI35958. PMC&nbsp;
2631294. PMID&nbsp;19164858. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2631294
.&nbsp;</li> 
<li><b>^</b> Chan, <i>et al.</i>; Ogino, S; Fuchs, CS (12 August 209). 
&quot;Aspirin Use and Survival After Diagnosis of Colorectal Cancer&quot;. <i>
JAMA</i> <b>302</b> (6): 649&ndash;658. doi:10.1001/jama.2009.1112. PMC&nbsp;
2848289. PMID&nbsp;19671906. 
http://jama.ama-assn.org/cgi/content/short/302/6/649?rss=1.&nbsp;</li> 
<li><b>^</b> Holmes, M.; <i>et al.</i> (2010). &quot;Aspirin intake and 
survival after breast cancer&quot;. <i>Journal of Clinical Oncology</i> <b>28
</b> (9): 1467&ndash;1472. doi:10.1200/JCO.2009.22.7918. PMC&nbsp;2849768. PMID
&nbsp;20159825. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2849768
.&nbsp;</li> 
<li><b>^</b> &quot;Is aspirin a miracle drug?&quot;. <i>ABC News</i>. 2010. 
http://abcnews.go.com/Health/video/aspirin-miracle-drug-9980248.&nbsp;</li> 
<li><b>^</b> Coomer, C. (2010). &quot;Aspirin battling breast cancer&quot;. <i>
Fox News Health Blog</i>. 
http://health.blogs.foxnews.com/2010/02/17/aspirin-battling-breast-cancer/.
&nbsp;</li> 
<li><b>^</b> &quot;Women warned aspirin reports may be misleading&quot;. <i>
National Prescribing Service</i>. 2010. 
http://www.nps.org.au/news_and_media/media_releases/repository/Women_warned_aspirin
.&nbsp;</li> 
<li><b>^</b> &quot;Small daily aspirin dose 'cuts cancer risk&quot;. <i>BBC 
News Health</i> (2010), available at http://www.bbc.co.uk/news/health-11930988
</li> 
<li><b>^</b> Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, 
Colby E, Montague D, Smyth SS (2007). &quot;Aspirin Resistance in Patients with 
Stable Coronary Artery Disease with and without a History of Myocardial 
Infarction&quot;.<i>Ann Pharmacother</i> <b>41</b> (May): 737. doi:
10.1345/aph.1H621. PMID&nbsp;17456544.&nbsp;</li> 
<li><b>^</b> Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008). 
&quot;Aspirin &quot;resistance&quot; and risk of cardiovascular morbidity: 
systematic review and meta-analysis&quot;. <i>BMJ</i> <b>336</b> (7637): 
195&ndash;8.doi:10.1136/bmj.39430.529549.BE. PMC&nbsp;2213873. PMID&nbsp;
18202034. http://bmj.com/cgi/pmidlookup?view=long&amp;pmid=18202034.&nbsp;</li> 
<li><b>^</b> Pignatelli P, Di Santo S, Barill&agrave; F, Gaudio C, Violi F 
(2008). &quot;Multiple anti-atherosclerotic treatments impair aspirin 
compliance: effects on aspirin resistance&quot;.<i>J. Thromb. Haemost.</i> <b>6
</b> (10): 1832&ndash;4. doi:10.1111/j.1538-7836.2008.03122.x. PMID&nbsp;
18680540.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i>British National Formulary</i> (45 
ed.).British Medical Journal and Royal Pharmaceutical Society of Great Britain. 
2003.&nbsp;</li> 
<li><b>^</b> &quot;Aspirin monograph: dosages, etc&quot;. Medscape.com. 
http://www.medscape.com/druginfo/monograph?cid=med&amp;drugid=3881&amp;drugname=Aspirin+EC+Oral&amp;monotype=monograph
. Retrieved 2011-05-11.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> &quot;Aspirin: More 
Evidence That Low Dose Is All That Is Needed (from Medscape)&quot;. 
Cme.medscape.com. http://cme.medscape.com/viewarticle/589895?src=cmemp. 
Retrieved 2011-05-11.&nbsp;</li> 
<li><b>^</b> <i>British National Formulary for Children</i>. British Medical 
Journal and Royal Pharmaceutical Society. 2006.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> <i><b>d</b></i> <i><b>e
</b></i> &quot;Aspirin information from Drugs.com&quot;. Drugs.com. 
http://www.drugs.com/aspirin.html. Retrieved 2008-05-08.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> &quot;Oral Aspirin 
information&quot;. First DataBank. http://www.personalmd.com/drgdb/3.htm. 
Retrieved 2008-05-08.&nbsp;</li> 
<li><b>^</b> Raithel M, Baenkler HW, Naegel A, <i>et al.</i> (September 2005). 
&quot;Significance of salicylate intolerance in diseases of the lower 
gastrointestinal tract&quot; (PDF). <i>J. Physiol. Pharmacol.</i> <b>56 Suppl 5
</b>: 89&ndash;102. PMID&nbsp;16247191. 
http://www.jpp.krakow.pl/journal/archive/09_05_s5/pdf/89_09_05_s5_article.pdf.
&nbsp;</li> 
<li><b>^</b> Senna GE, Andri G, Dama AR, Mezzelani P, Andri L (1995). 
&quot;Tolerability of imidazole salycilate in aspirin-sensitive patients&quot;. 
<i>Allergy Proc</i> <b>16</b> (5): 251&ndash;4. doi:10.2500/108854195778702675. 
PMID&nbsp;8566739. 
http://openurl.ingenta.com/content/nlm?genre=article&amp;issn=1088-5412&amp;volume=16&amp;issue=5&amp;spage=251&amp;aulast=Senna
.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> &quot;PDR Guide to Over the Counter 
(OTC) Drugs&quot;. 
http://www.mercksource.com/pp/us/cns/cns_hl_pdr.jspzQzpgzEzzSzppdocszSzuszSzcnszSzcontentzSzpdrotczSzotc_fullzSzdrugszSzfgotc036zPzhtm
. Retrieved 2008-04-28.&nbsp;</li> 
<li><b>^</b> Frank B. Livingstone. (1985). <i>Frequencies of hemoglobin 
variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD 
variants, and ovalocytosis in human populations</i>. Oxford University Press. 
ISBN&nbsp;0195036344. 
http://books.google.com/?id=OjqNeJERhWwC&amp;q=0195036344&amp;dq=0195036344. 
Retrieved 2011-05-07.&nbsp;</li> 
<li><b>^</b> &quot;Dengue and Dengue Hemorrhagic Fever: Information for Health 
Care Practitioners&quot;. http://www.cdc.gov/NCIDOD/dvbid/dengue/dengue-hcp.htm
. Retrieved 2008-04-28.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> S&oslash;rensen HT, 
Mellemkjaer L, Blot WJ,<i>et al.</i> (2000). &quot;Risk of upper 
gastrointestinal bleeding associated with use of low-dose aspirin&quot;. <i>Am. 
J. Gastroenterol.</i> <b>95</b> (9): 2218&ndash;24. doi:
10.1111/j.1572-0241.2000.02248.x. PMID&nbsp;11007221. 
http://www.blackwell-synergy.com/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0002-9270&amp;date=2000&amp;volume=95&amp;issue=9&amp;spage=2218
.&nbsp;</li> 
<li><b>^</b> Delaney JA, Opatrny L, Brophy JM &amp; Suissa S (2007). 
&quot;Drug drug interactions between antithrombotic medications and the risk of 
gastrointestinal bleeding&quot;. <i>CMAJ</i> <b>177</b> (4): 347&ndash;51. doi:
10.1503/cmaj.070186. PMC&nbsp;1942107. PMID&nbsp;17698822. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1942107
.&nbsp;</li> 
<li><b>^</b> &quot;General Chemistry Online: FAQ: Acids and bases: What is the 
buffer system in buffered aspirin?&quot;. Antoine.frostburg.edu. 
http://antoine.frostburg.edu/chem/senese/101/acidbase/faq/buffered-aspirin.shtml
. Retrieved 2011-05-11.&nbsp;</li> 
<li><b>^</b> Dammann<i>et al.</i> (2004). &quot;Effects of buffered and plain 
acetylsalicylic acid formulations with and without ascorbic acid on gastric 
mucosa in healthy subjects&quot;.<i>Aliment Pharmacol Ther.</i> (19): 
367&ndash;74.&nbsp;</li> 
<li><b>^</b> Konturek<i>et al.</i>; Kania, J; Hahn, EG; Konturek, JW (2006). 
&quot;Ascorbic acid attenuates aspirin-induced gastric damage: role of 
inducible nitric oxide synthase&quot;. <i>J Physiol Pharmacol.</i> <b>57 Suppl 5
</b> (5): 125&ndash;36. PMID&nbsp;17218764. 
http://www.ncbi.nlm.nih.gov/pubmed/17218764.&nbsp;</li> 
<li><b>^</b> Reese<i>et al.</i> (1979). &quot;Effect of deglycyrrhinized 
liquorice on gastric mucosal damage by aspirin&quot;.<i>Scand J Gastroenterol
</i> (14): 605&ndash;07.&nbsp;</li> 
<li><b>^</b> Laudanno <i>et al.</i> (1984). &quot;Prostaglandin E1 
(misoprostol) and S-adenosylmethionine in the prevention of hemorrhagic 
gastritis induced by aspirin in the human. Endoscopic, histologic and 
histochemical study&quot;.<i>Acta Gastroenterol Latinoam</i> (14): 289&ndash;93.
&nbsp;</li> 
<li><b>^</b> Kevin J. Ivey, Douglas B. Paone and William J. Krause, Digestive 
Diseases and Sciences 25, 97-99,doi:10.1007/BF01308304, Acute effect of 
systemic aspirin on gastric mucosa in man</li> 
<li><b>^</b> Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL (2003).
&quot;Salicylate induces tinnitus through activation of cochlear NMDA 
receptors&quot;. <i>J. Neurosci.</i> <b>23</b> (9): 3944&ndash;52. PMID&nbsp;
12736364. http://www.jneurosci.org/cgi/content/full/23/9/3944.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Belay ED, Bresee JS, Holman RC, Khan AS, 
Shahriari A, Schonberger LB (1999).&quot;Reye's syndrome in the United States 
from 1981 through 1997&quot;. <i>N. Engl. J. Med.</i> <b>340</b> (18): 
1377&ndash;82.doi:10.1056/NEJM199905063401801. PMID&nbsp;10228187. 
http://content.nejm.org/cgi/pmidlookup?view=short&amp;pmid=10228187&amp;promo=ONFLNS19
.&nbsp;</li> 
<li><b>^</b> NHS Choices: Reye's syndrome. Last reviewed: 16 December 2008 
http://www.nhs.uk/conditions/Reyes-syndrome/Pages/Introduction.aspx</li> 
<li><b>^</b> Berges-Gimeno MP &amp; Stevenson DD (2004). &quot;Nonsteroidal 
anti-inflammatory drug-induced reactions and desensitization&quot;.<i>J Asthma
</i> <b>41</b> (4): 375&ndash;84. doi:10.1081/JAS-120037650. PMID&nbsp;15281324.
&nbsp;</li> 
<li><b>^</b> Vernooij MW, Haag MD, der Lugt A, Hofman A, Krestin GP, Stricker 
BH, Breteler MM (2009). &quot;Use of antithrombotic drugs and the presence of 
cerebral microbleeds: the Rotterdam Scan Study&quot;.<i>Arch Neurol</i> <b>66
</b> (6): 714&ndash;20. doi:10.1001/archneurol.2009.42. PMID&nbsp;19364926.
&nbsp;</li> 
<li><b>^</b> Gorelick PB (2009). &quot;Cerebral microbleeds: evidence of 
heightened risk associated with aspirin use&quot;.<i>Arch Neurol</i> <b>66</b> 
(6): 691&ndash;3.doi:10.1001/archneurol.2009.85. PMID&nbsp;19506128.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> He, J.; Whelton, P. K.; Vu, B.; Klag, M. 
J. (1998). &quot;Aspirin and risk of hemorrhagic stroke: A meta-analysis of 
randomized controlled trials&quot;.<i>JAMA&nbsp;: the journal of the American 
Medical Association</i> <b>280</b> (22): 1930&ndash;1935. PMID&nbsp;9851479.
&nbsp;&nbsp;edit</li> 
<li><b>^</b> Saloheimo, P.; Ahonen, M.; Juvela, S.; Pyhtinen, J.; Savolainen, 
E. R.; Hillbom, M. (2005). &quot;Regular Aspirin-Use Preceding the Onset of 
Primary Intracerebral Hemorrhage is an Independent Predictor for Death&quot;.<i>
Stroke</i> <b>37</b> (1): 129&ndash;133. doi:10.1161/01.STR.0000196991.03618.31.
PMID&nbsp;16322483.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Medical knowledge self-assessment program for students 4, By 
American College of Physicians, Clerkship Directors in Internal Medicine, 
Nephrology 227, Item 29</li> 
<li><b>^</b> Scher, K.S. (1996). &quot;Unplanned reoperation for 
bleeding&quot;.<i>Am Surg</i> <b>62</b> (1): 52&ndash;55. PMID&nbsp;8540646.
&nbsp;</li> 
<li><b>^</b> Gaudreault P, Temple AR, Lovejoy FH Jr (1982). &quot;The relative 
severity of acute versus chronic salicylate poisoning in children: a clinical 
comparison&quot;.<i>Pediatrics</i> <b>70</b> (4): 566&ndash;9. PMID&nbsp;7122154
.&nbsp; (primary source)[<i>unreliable medical source?</i>]</li> 
<li><b>^</b> Marx, John (2006). <i>Rosen's emergency medicine: concepts and 
clinical practice</i>. Mosby/Elsevier. p.&nbsp;2242. ISBN&nbsp;9780323028455.
&nbsp;</li> 
<li><b>^</b> Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA 
(1996). &quot;Serum concentrations of salicylic acid following topically 
applied salicylate derivatives&quot;.<i>Ann. Pharmacother</i> <b>30</b> (9): 
935&ndash;40.PMID&nbsp;8876850.&nbsp;</li> 
<li><b>^</b> R. Baselt (2008). <i>Disposition of Toxic Drugs and Chemicals in 
Man</i> (8th ed.). Foster City, California: Biomedical Publications. 
pp.&nbsp;22&ndash;5.&nbsp;</li> 
<li><b>^</b> &quot;Information for Healthcare Professionals: Concomitant Use 
of Ibuprofen and Aspirin&quot;. <i>FDA</i>. U.S. Department of Health &amp; 
Human Services. 2006-09. 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222.htm
. Retrieved 2010-11-22.&nbsp;</li> 
<li><b>^</b> Katzung (1998), p. 584.</li> 
<li><b>^</b> Loh HS, Watters K &amp; Wilson CW (1 November 1973). &quot;The 
Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human 
Beings&quot;. <i>J Clin Pharmacol</i> <b>13</b> (11): 480&ndash;6. PMID&nbsp;
4490672. http://jcp.sagepub.com/cgi/content/abstract/13/11/480.&nbsp;</li> 
<li><b>^</b> Basu TK (1982). &quot;Vitamin C-aspirin interactions&quot;. <i>
Int J Vitam Nutr Res Suppl</i> <b>23</b>: 83&ndash;90. PMID&nbsp;6811490.&nbsp;
</li> 
<li><b>^</b> Ioannides C, Stone AN, Breacker PJ &amp; Basu TK (1982). 
&quot;Impairment of absorption of ascorbic acid following ingestion of aspirin 
in guinea pigs&quot;.<i>Biochem Pharmacol</i> <b>31</b> (24): 4035&ndash;8. doi:
10.1016/0006-2952(82)90652-9. PMID&nbsp;6818974.&nbsp;</li> 
<li><b>^</b> Reynolds EF (ed) (1982). Aspirin and similar analgesic and 
anti-inflammatory agents. Martindale, The Extra Pharmacopoeia 28 Ed, 234-82.
</li> 
<li><b>^</b> Palleros, Daniel R. (2000). <i>Experimental Organic Chemistry</i>
. New York: John Wiley &amp; Sons. p.&nbsp;494.ISBN&nbsp;0-471-28250-2.&nbsp;
</li> 
<li><b>^</b> Barrans, Richard. &quot;Aspirin Aging&quot;. Newton BBS. 
http://www.newton.dep.anl.gov/askasci/chem00/chem00314.htm. Retrieved 2008-05-08
.&nbsp;</li> 
<li><b>^</b> Carstensen, J.T.; F Attarchi and XP Hou (1985). 
&quot;Decomposition of aspirin in the solid state in the presence of limited 
amounts of moisture&quot;.<i>Journal of Pharmaceutical Sciences</i> <b>77</b> 
(4): 318&ndash;21.doi:10.1002/jps.2600770407. PMID&nbsp;4032246.&nbsp;</li> 
<li><b>^</b> &quot;Acetylsalicylic acid&quot;. Jinno Laboratory, School of 
Materials Science, Toyohashi University of Technology. March 4, 1996. 
http://chrom.tutms.tut.ac.jp/JINNO/DRUGDATA/07acetylsalicylic_acid.html. 
Retrieved 2007-09-07.&nbsp;</li> 
<li><b>^</b> Peddy Vishweshwar, Jennifer A. McMahon, Mark Oliveira, Matthew L. 
Peterson, and Michael J. Zaworotko (2005). &quot;The Predictably Elusive Form 
II of Aspirin&quot;.<i>J. Am. Chem. Soc.</i> <b>127</b> (48): 16802&ndash;16803.
doi:10.1021/ja056455b. PMID&nbsp;16316223.&nbsp;</li> 
<li><b>^</b> Andrew D. Bond, Roland Boese, Gautam R. Desiraju (2007). &quot;On 
the Polymorphism of Aspirin: Crystalline Aspirin as Intergrowths of Two 
&quot;Polymorphic&quot; Domains&quot;.<i>Angewandte Chemie International Edition
</i> <b>46</b> (4): 618&ndash;622. doi:10.1002/anie.200603373. PMID&nbsp;
17139692.&nbsp;</li> 
<li><b>^</b> John Robert Vane (1971). &quot;Inhibition of prostaglandin 
synthesis as a mechanism of action for aspirin-like drugs&quot;.<i>Nature - New 
Biology</i> <b>231</b> (25): 232&ndash;5. PMID&nbsp;5284360.&nbsp;</li> 
<li><b>^</b> Vane JR, Botting RM (2003). &quot;The mechanism of action of 
aspirin&quot; (PDF). <i>Thromb Res</i> <b>110</b> (5&ndash;6): 255&ndash;8. doi:
10.1016/S0049-3848(03)00379-7. PMID&nbsp;14592543. 
http://www.eao.chups.jussieu.fr/polys/certifopt/saule_coxib/theme/1vane2003.pdf.
&nbsp;</li> 
<li><b>^</b> &quot;Aspirin in Heart Attack and Stroke Prevention&quot;. 
American Heart Association. 
http://www.americanheart.org/presenter.jhtml?identifier=4456. Retrieved 
2008-05-08.&nbsp;</li> 
<li><b>^</b> Tohgi, H; S Konno, K Tamura, B Kimura and K Kawano (1992). 
&quot;Effects of low-to-high doses of aspirin on platelet aggregability and 
metabolites of thromboxane A2 and prostacyclin&quot;.<i>Stroke</i> <b>23</b> 
(10): 1400&ndash;1403.doi:10.1161/01.STR.23.10.1400. PMID&nbsp;1412574.&nbsp;
</li> 
<li><b>^</b> Somasundaram, S. et al.; Sigthorsson, G; Simpson, RJ; Watts, J; 
Jacob, M; Tavares, IA; Rafi, S; Roseth, A et al (2000). &quot;Uncoupling of 
intestinal mitochondrial oxidative phosphorylation and inhibition of 
cyclooxygenase are required for the development of NSAID-enteropathy in the 
rat&quot;.<i>Aliment Pharmacol Ther</i> <b>14</b> (5): 639&ndash;650. doi:
10.1046/j.1365-2036.2000.00723.x. PMID&nbsp;10792129.&nbsp;</li> 
<li><b>^</b> Paul-Clark, Mark J.; Cao, Thong van; Moradi-Bidhendi, Niloufar; 
Cooper, Dianne &amp; Gilroy, Derek W. (2004).&quot;15-epi-lipoxin 
A4&ndash;mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute 
Inflammation&quot;. <i>J. Exp. Med.</i> <b>200</b> (1): 69&ndash;78. doi:
10.1084/jem.20040566. PMC&nbsp;2213311. PMID&nbsp;15238606. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=2213311
.&nbsp;</li> 
<li><b>^</b> McCarty, M. F.; Block, K. I. (2006). &quot;Preadministration of 
high-dose salicylates, suppressors of NF-kappaB activation, may increase the 
chemosensitivity of many cancers: an example of proapoptotic signal modulation 
therapy&quot;.<i>Integr Cancer Ther.</i> <b>5</b> (3): 252&ndash;268. doi:
10.1177/1534735406291499. PMID&nbsp;16880431.&nbsp;</li> 
<li><b>^</b> Caviezel, F; Cattaneo, AG; Tell, A; Corino, T; Mascherpa, M 
(1983). &quot;The effect of acetylsalicylic acid and diclofenac on stimulated 
growth hormone and prolactin secretion in humans&quot;.<i>International journal 
of clinical pharmacology, therapy, and toxicology</i> <b>21</b> (10): 
502&ndash;4.PMID&nbsp;6642786.&nbsp;&nbsp;edit</li> 
<li><b>^</b> Ramey, JN; Burrow, GN; Spaulding, SW; Donabedian, RK; Speroff, L; 
Frantz, AG (1976). &quot;The effect of aspirin and indomethacin on the TRH 
response in man&quot;.<i>The Journal of clinical endocrinology and metabolism
</i> <b>43</b> (1): 107&ndash;14. doi:10.1210/jcem-43-1-107. PMID&nbsp;820703.
&nbsp;&nbsp;edit</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> Nye EJ, Hockings GI, Grice JE, Torpy DJ, 
Walters MM, Crosbie GV, Wagenaar M, Cooper M, Jackson RV (1997). &quot;Aspirin 
inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal 
humans&quot;.<i>J. Clin. Endocrinol. Metab.</i> <b>82</b> (3): 812&ndash;7. doi:
10.1210/jc.82.3.812. PMID&nbsp;9062488.&nbsp;</li> 
<li><b>^</b> Hockings GI, Grice JE, Crosbie GV, Walters MM, Jackson AJ, 
Jackson RV (1993). &quot;Aspirin increases the human 
hypothalamic-pituitary-adrenal axis response to naloxone stimulation&quot;.<i>
J. Clin. Endocrinol. Metab.</i> <b>77</b> (2): 404&ndash;8. doi:
10.1210/jc.77.2.404. PMID&nbsp;8393884.&nbsp;</li> 
<li><b>^</b> Ferguson, RK; Boutros, AR (1970-08-17). &quot;Death following 
self-poisoning with aspirin&quot;.<i>Journal of the American Medical Association
</i> <b>213</b> (7): 1186&ndash;8. doi:10.1001/jama.213.7.1186. PMID&nbsp;
5468267.&nbsp;</li> 
<li><b>^</b> Kaufman, FL; Dubansky, AS (1970-04). &quot;Darvon poisoning with 
delayed salicylism: a case report&quot;.<i>Pediatrics</i> <b>49</b> (4): 
610&ndash;1.PMID&nbsp;5013423.&nbsp;</li> 
<li>^ <i><b>a</b></i> <i><b>b</b></i> <i><b>c</b></i> Levy, G; Tsuchiya, T 
(1972-09-31). &quot;Salicylate accumulation kinetics in man&quot;.<i>New 
England Journal of Medicine</i> <b>287</b> (9): 430&ndash;2. doi:
10.1056/NEJM197208312870903. PMID&nbsp;5044917.&nbsp;</li> 
<li><b>^</b> 2,3-Dihydroxybenzoic acid is a product of human aspirin 
metabolism. Martin Grootveld and Barry Halliwell, Biochemical Pharmacology, 
Volume 37, Issue 2, 15 January 1988, pages 271-280,doi:
10.1016/0006-2952(88)90729-0</li> 
<li><b>^</b> Hartwig, Otto H (1983-11-14). &quot;Pharmacokinetic 
considerations of common analgesics and antipyretics&quot;.<i>American Journal 
of Medicine</i> <b>75</b> (5A): 30&ndash;7. doi:10.1016/0002-9343(83)90230-9. 
PMID&nbsp;6606362.&nbsp;</li> 
<li><b>^</b> Done, AK (1960-11). &quot;Salicylate intoxication. Significance 
of measurements of salicylate in blood in cases of acute ingestion&quot;.<i>
Pediatrics</i> <b>26</b>: 800&ndash;7. PMID&nbsp;13723722.&nbsp;</li> 
<li><b>^</b> Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra 
AS, Caravati EM, Nelson LS, Olson KR, Cobaugh DJ, Scharman EJ, Woolf AD, 
Troutman WG; Americal Association of Poison Control Centers; Healthcare Systems 
Bureau, Health Resources and Services Administration, Department of Health and 
Human Services. (2007). &quot;Salicylate poisoning: an evidence-based consensus 
guideline for out-of-hospital management&quot;.<i>Clin Toxicol (Phila)</i> <b>45
</b> (2): 95&ndash;131. doi:10.1080/15563650600907140. PMID&nbsp;17364628.&nbsp;
</li> 
<li><b>^</b> Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot 
AT (1982).&quot;Diuresis or urinary alkalinisation for salicylate 
poisoning?&quot;. <i>Br Med J (Clin Res Ed)</i> <b>285</b> (6352): 1383&ndash;6.
doi:10.1136/bmj.285.6352.1383. PMC&nbsp;1500395. PMID&nbsp;6291695. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1500395
.&nbsp;</li> 
<li><b>^</b> Dargan PI, Wallace CI, Jones AL. (2002). &quot;An evidenced based 
flowchart to guide the management of acute salicylate (aspirin) overdose&quot;. 
<i>Emerg Med J</i> <b>19</b> (3): 206&ndash;9. doi:10.1136/emj.19.3.206. PMC
&nbsp;1725844. PMID&nbsp;11971828. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1725844
.&nbsp;</li> 
<li><b>^</b> Mary Bellis (2010-06-16). &quot;History of aspirin&quot;. 
Inventors.about.com. http://inventors.about.com/library/inventors/blaspirin.htm
. Retrieved 2011-05-11.&nbsp;</li> 
<li><b>^</b> (German) Gerhardt C (1853). &quot;Untersuchungen &uuml;ber die 
wasserfreien organischen S&auml;uren&quot;.<i>Annalen der Chemie und Pharmacie
</i> <b>87</b>: 149&ndash;179. doi:10.1002/jlac.18530870107.&nbsp;</li> 
<li><b>^</b> (German) von Gilm H (1859). &quot;Acetylderivate der Phloretin- 
und Salicyls&auml;ure&quot;.<i>Annalen der Chemie und Pharmacie</i> <b>112</b> 
(2): 180&ndash;185.doi:10.1002/jlac.18591120207.&nbsp;</li> 
<li><b>^</b> (German)Schr&ouml;der, Prinzhorn, Kraut K (1869). &quot;Uber 
Salicylverbindungen&quot;.<i>Annalen der Chemie und Pharmacie</i> <b>150</b> 
(1): 1&ndash;20.doi:10.1002/jlac.18691500102.&nbsp;</li> 
<li><b>^</b> Mahdi, JG; Mahdi, AJ, Mahdi, AJ, Bowen, ID (2006 Apr). &quot;The 
historical analysis of aspirin discovery, its relation to the willow tree and 
antiproliferative and anticancer potential.&quot;.<i>Cell proliferation</i> <b>
39</b> (2): 147&ndash;55. doi:10.1111/j.1365-2184.2006.00377.x. PMID&nbsp;
16542349.&nbsp;</li> 
<li><b>^</b> Sneader W (2000 Dec 23-30). &quot;The discovery of aspirin: a 
reappraisal&quot;. <i>BMJ</i> <b>321</b> (7276): 1591&ndash;4. doi:
10.1136/bmj.321.7276.1591. PMC&nbsp;1119266. PMID&nbsp;11124191. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1119266
.&nbsp;</li> 
<li><b>^</b> Jeffreys, Diarmuid (August 11, 2005). <i>Aspirin: The Remarkable 
Story of a Wonder Drug</i>. Bloomsbury USA. p.&nbsp;73. ISBN&nbsp;1582346003.
&nbsp;</li> 
<li><b>^</b> Singer, H. (1901). &quot;Ueber Aspirin&quot;. <i>Pfl&uuml;gers 
Archiv: European Journal of Physiology</i> <b>84</b> (11-12): 527&ndash;546. doi
:10.1007/BF01769129.&nbsp;</li> 
<li><b>^</b> Starko, Karen M. (2009). &quot;Salicylates and Pandemic Influenza 
Mortality, 1918&ndash;1919 Pharmacology, Pathology, and Historic Evidence&quot;.
<i>Clinical Infectious Diseases</i> <b>49</b> (9): 1405. doi:10.1086/606060.
&nbsp;</li> 
<li><b>^</b> Jeffreys, <i>Aspirin</i>, pp. 136&ndash;142 and 151-152</li> 
<li><b>^</b> &quot;Bayer patents aspirin &mdash; History.com This Day in 
History &mdash; 3/6/1899&quot;. History.com. 
http://www.history.com/this-day-in-history.do?action=VideoArticle&amp;id=52415. 
Retrieved 2011-05-11.&nbsp;</li> 
<li><b>^</b> Jeffreys, <i>Aspirin</i>, pp. 212&ndash;217</li> 
<li><b>^</b> Jeffreys, <i>Aspirin</i>, pp. 226&ndash;231</li> 
<li><b>^</b> Jeffreys, <i>Aspirin</i>, pp. 267&ndash;269</li> 
<li><b>^</b> &quot;Treaty of Versailles, Part X, Section IV, Article 298&quot;
. 1919-06-28. pp. Annex, Paragraph 5. 
http://en.wikisource.org/wiki/Treaty_of_Versailles/Part_X#Article_298. 
Retrieved 2008-10-25.&nbsp;</li> 
<li><b>^</b> Mehta, Aalok (2005). &quot;Aspirin&quot;. <i>Chemical &amp; 
Engineering News</i> <b>83</b> (25). 
http://pubs.acs.org/cen/coverstory/83/8325/8325aspirin.html. Retrieved 
2008-10-23.&nbsp;</li> 
<li><b>^</b> &quot;The Centenary of Aspirin&quot;. Ul.ie. 1999-03-06. 
http://www.ul.ie/~childsp/CinA/Issue59/TOC43_Aspirin.htm. Retrieved 2011-05-11.
&nbsp;</li> 
<li><b>^</b> CBE Style Manual Committee; Huth, Edward J. (1994). <i>Scientific 
Style and Format: The CBE Manual for Authors, Editors, and Publishers</i>. 
Cambridge University Press. p.&nbsp;164.ISBN&nbsp;9780521471541. 
http://books.google.com/books?id=PoFJ-OhE63UC&amp;pg=PA164.&nbsp;</li> 
<li><b>^</b> &quot;Aspirin: the versatile drug&quot;. <i>CBC News</i>. 
2009-05-28. http://www.cbc.ca/health/story/2009/05/28/f-aspirin-studies.html.
&nbsp;</li> 
<li><b>^</b> Cheng, Tsung O. (2007). &quot;The History of Aspirin&quot;. <i>
Texas Heart Institute Journal</i> <b>34</b> (3): 392&ndash;393. PMC&nbsp;1995051
.PMID&nbsp;17948100. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1995051
.&nbsp;</li> 
<li><b>^</b> Sigma Aldrich. &quot;Aspirin&quot;. 
http://www.sigmaaldrich.com/catalog/ProductDetail.do?lang=en&amp;N4=A2093. 
Retrieved 13 July 2009.&nbsp;</li> 
<li><b>^</b> British Pharmacopoeia. &quot;Index BP 2009&quot;. 
http://www.pharmacopoeia.co.uk/pdf/2009_index.pdf. Retrieved 13 July 2009.&nbsp;
</li> 
<li><b>^</b> Crosby, Janet Tobiassen (2006). &quot;Veterinary Questions and 
Answers&quot;. About.com. 
http://vetmedicine.about.com/cs/altvetmedgeneral/a/dogcataspirin.htm. Retrieved 
2007-09-05.&nbsp;</li> 
<li><b>^</b> Cambridge H, Lees P, Hooke RE, Russell CS (1991). 
&quot;Antithrombotic actions of aspirin in the horse&quot;.<i>Equine Vet J</i> 
<b>23</b> (2): 123&ndash;7. doi:10.1111/j.2042-3306.1991.tb02736.x. PMID&nbsp;
1904347.&nbsp;</li> 
<li><b>^</b> Lappin, [edited by] Michael R. (2001). <i>Feline internal 
medicine secrets</i>. Philadelphia: Hanley &amp; Belfus. p.&nbsp;160. ISBN&nbsp;
1-56053-461-3.&nbsp;</li> </ol> 
<h2>[edit] External links</h2> Wikimedia Commons has media related to: <i><b>
Aspirin</b></i> <br>
<br>

<ul> 
<li>NextBio Aspirin Entry</li> 
<li>Interactive 3D-structure of aspirin with detailed x-ray crystal structure 
data</li> 
<li>The History of Aspirin</li> 
<li>How Aspirin works</li> 
<li>The science behind aspirin</li> 
<li>Take two: Aspirin, New uses and new dangers are still being discovered as 
aspirin enters its 2nd century. Shauna Roberts, American Chemical Society</li> 
<li>Ling, Greg (2005). &quot;Aspirin&quot;. <i>How Products are Made</i>. <b>1
</b>. Thomson Gale. http://www.madehow.com/Volume-1/Aspirin.html.&nbsp;</li> 
<li>U.S. National Library of Medicine: Drug Information Portal - Aspirin</li> 
</ul> 
<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Antithrombotics ( thrombolytics) <br>
<br>
<br>
Antiplatelet 
drugs <br>
Glycoprotein IIb/IIIa inhibitors <br>

<ul> 
<li>Abciximab</li> 
<li>Eptifibatide</li> 
<li>Tirofiban</li> </ul> <br>
<br>
ADP receptor/P2Y12 inhibitors <br>

<ul> 
<li><i>thienopyridines</i> (Clopidogrel</li> 
<li>Prasugrel</li> 
<li>Ticlopidine)</li> 
<li><i>nucleotide/nucleoside analogs</i> (Cangrelor</li> 
<li>Elinogrel</li> 
<li>Ticagrelor)</li> </ul> <br>
<br>
Prostaglandin analogue ( PGI2) <br>

<ul> 
<li>Beraprost</li> 
<li>Prostacyclin</li> 
<li>Iloprost</li> 
<li>Treprostinil</li> </ul> <br>
<br>
COX inhibitors <br>

<ul> 
<li><strong>Acetylsalicylic acid/Aspirin</strong>#</li> 
<li>Aloxiprin</li> 
<li>Carbasalate calcium</li> 
<li>Indobufen</li> 
<li>Triflusal</li> </ul> <br>
<br>
Thromboxane inhibitors <br>

<ul> 
<li><i>thromboxane synthase inhibitors</i> (Dipyridamole</li> 
<li>Picotamide)</li> 
<li><i>receptor antagonist</i> (Terutroban&dagger;)</li> </ul> <br>
<br>

Phosphodiesterase inhibitors <br>

<ul> 
<li>Cilostazol</li> 
<li>Dipyridamole</li> 
<li>Triflusal</li> </ul> <br>
<br>
 Other 
<ul> 
<li>Cloricromen</li> 
<li>Ditazole</li> </ul> <br>
<br>
<br>
<br>
Anticoagulants <br>
Vitamin K 
antagonists <br>
 (inhibit II, VII, IX, X) <br>

<ul> 
<li><i>coumarins:</i> Acenocoumarol</li> 
<li>Coumatetralyl</li> 
<li>Dicoumarol</li> 
<li>Ethyl biscoumacetate</li> 
<li>Phenprocoumon</li> 
<li>Warfarin#</li> </ul> 
<ul> 
<li><i>1,3-Indandiones:</i> Clorindione</li> 
<li>Diphenadione</li> 
<li>Phenindione</li> </ul> <i>other:</i> Tioclomarol <br>
<br>
<br>
Factor Xa 
inhibitors<br>
 (with some II inhibition) <br>
Heparin group/ <br>

glycosaminoglycans/ <br>
 (bind antithrombin) <br>

<ul> 
<li><i>low-molecular-weight heparin</i> (Bemiparin</li> 
<li>Certoparin</li> 
<li>Dalteparin</li> 
<li>Enoxaparin</li> 
<li>Nadroparin</li> 
<li>Parnaparin</li> 
<li>Reviparin</li> 
<li>Tinzaparin)</li> </ul> 
<ul> 
<li><i>oligosaccharides</i> (Fondaparinux</li> 
<li>Idraparinux)</li> </ul> 
<ul> 
<li><i>heparinoid</i> (Danaparoid</li> 
<li>Sulodexide</li> 
<li>Dermatan sulfate)</li> </ul> <br>
<br>
Direct Xa inhibitors <br>

<ul> 
<li><i>xabans</i> (Apixaban</li> 
<li>Betrixaban</li> 
<li>Edoxaban</li> 
<li>Otamixaban</li> 
<li>Rivaroxaban)</li> </ul> <br>
<br>
<br>
<br>
Direct thrombin (II) inhibitors
<br> 
<ul> 
<li><i>bivalent:</i> Hirudin (Bivalirudin</li> 
<li>Lepirudin</li> 
<li>Desirudin)<br>
</li> </ul> 
<ul> 
<li><i>univalent:</i> Argatroban</li> 
<li>Dabigatran</li> 
<li>Melagatran&Dagger;</li> 
<li>Ximelagatran&Dagger;</li> </ul> <br>
<br>
 Other 
<ul> 
<li>REG1</li> 
<li>Defibrotide</li> 
<li>Ramatroban</li> 
<li>Antithrombin III</li> 
<li>Protein C (Drotrecogin alfa)</li> </ul> <br>
<br>
<br>
<br>
Thrombolytic 
drugs/<br>
fibrinolytics 
<ul> 
<li><i>plasminogen activators:</i> <i>r-tPA</i> (Alteplase</li> 
<li>Reteplase</li> 
<li>Tenecteplase)</li> 
<li><i>UPA</i> (Urokinase</li> 
<li>Saruplase)</li> 
<li>Streptokinase#</li> 
<li>Anistreplase</li> 
<li>Monteplase</li> </ul> 
<ul> 
<li><i>other serine endopeptidases:</i> Ancrod</li> 
<li>Fibrinolysin</li> 
<li>Brinase</li> </ul> <br>
<br>
Non-medicinal 
<ul> 
<li>Citrate</li> 
<li>EDTA</li> 
<li>Oxalate</li> </ul> <br>
<br>

<ul> 
<li>#WHO-EM</li> 
<li>&Dagger;Withdrawn from market</li> 
<li>Clinical trials: 
<ul> 
<li>&dagger;Phase III</li> 
<li>&sect;Never to phase III</li> </ul> </li> </ul> 
<p>M: MYL</p> 
<p>cell/phys (coag, heme, immu, gran), csfs</p> 
<p>rbmg/mogr/tumr/hist, sysi/epon, btst</p> 
<p>drug (B1/2/3+5+6), btst, trns</p> <br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>

<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Anti-inflammatory products ( M01A) <br>
<br>
<br>

Pyrazolidine/Butylpyrazolidines 
<ul> 
<li>Ampyrone</li> 
<li>Clofezone</li> 
<li>Kebuzone</li> 
<li>Metamizole</li> 
<li>Mofebutazone</li> 
<li>Oxyphenbutazone</li> 
<li>Phenazone</li> 
<li>Phenylbutazone</li> 
<li>Sulfinpyrazone</li> 
<li>Feprazone</li> </ul> <br>
<br>
Acetic acid derivatives<br>
 and related 
substances 
<ul> 
<li>Aceclofenac</li> 
<li>Acemetacin</li> 
<li>Alclofenac</li> 
<li>Bromfenac</li> 
<li>Bumadizone</li> 
<li>Bufexamac</li> 
<li>Diclofenac</li> 
<li>Difenpiramide</li> 
<li>Etodolac</li> 
<li>Fentiazac</li> 
<li>Indometacin</li> 
<li>Ketorolac</li> 
<li>Lonazolac</li> 
<li>Oxametacin</li> 
<li>Proglumetacin</li> 
<li>Sulindac</li> 
<li>Tolmetin</li> 
<li>Zomepirac</li> 
<li>Amfenac</li> </ul> <br>
<br>
Oxicams 
<ul> 
<li>Ampiroxicam</li> 
<li>Droxicam</li> 
<li>Lornoxicam</li> 
<li>Meloxicam</li> 
<li>Piroxicam</li> 
<li>Tenoxicam</li> </ul> <br>
<br>
Propionic acid derivatives 
<ul> 
<li>Alminoprofen</li> 
<li>Benoxaprofen</li> 
<li>Dexibuprofen</li> 
<li>Dexketoprofen</li> 
<li>Fenbufen</li> 
<li>Fenoprofen</li> 
<li>Flunoxaprofen</li> 
<li>Flurbiprofen</li> 
<li>Ibuprofen</li> 
<li>Ibuproxam</li> 
<li>Indoprofen</li> 
<li>Ketoprofen</li> 
<li>Naproxen</li> 
<li>Oxaprozin</li> 
<li>Pirprofen</li> 
<li>Suprofen</li> 
<li>Tiaprofenic acid</li> </ul> <br>
<br>
Fenamates 
<ul> 
<li>Flufenamic acid</li> 
<li>Meclofenamic acid</li> 
<li>Mefenamic acid</li> 
<li>Tolfenamic acid</li> 
<li>Niflumic acid</li> 
<li>Morniflumate</li> 
<li>Azapropazone</li> </ul> <br>
<br>
Coxibs 
<ul> 
<li>Celecoxib</li> 
<li>Etoricoxib</li> 
<li>Lumiracoxib</li> 
<li>Parecoxib</li> 
<li>Rofecoxib</li> 
<li>Valdecoxib</li> </ul> <br>
<br>
Other 
<ul> 
<li>Nabumetone</li> 
<li>Glucosamine</li> 
<li>Benzydamine</li> 
<li>Glycosaminoglycan</li> 
<li>Magnesium salicylate</li> 
<li>Proquazone</li> 
<li>Superoxide dismutase/Orgotein</li> 
<li>Nimesulide</li> 
<li>Diacerein</li> 
<li>Tenidap</li> 
<li>Oxaceprol</li> 
<li>Chondroitin sulfate</li> </ul> <br>
<br>

<p>M: MUS, DF+DRCT</p> 
<p>anat (h/n, u, t/d, a/p, l)/phys/devp/hist</p> 
<p>noco(m, s, c)/cong(d)/tumr, sysi/epon, injr</p> 
<p>proc, drug (M1A/3)</p> <br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>

<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Non-steroidal anti-inflammatory drug (NSAID) products 
(primarilyM01A and M02A, also N02BA) <br>
<br>
<br>
Salicylates 
<ul> 
<li><b><strong>Aspirin (acetylsalicylic acid)</strong></b></li> 
<li>Aloxiprin</li> 
<li>Benorylate</li> 
<li>Diflunisal</li> 
<li>Ethenzamide</li> 
<li>Magnesium salicylate</li> 
<li>Methyl salicylate</li> 
<li>Salsalate</li> 
<li>Salicin</li> 
<li>Salicylamide</li> 
<li>Sodium salicylate</li> </ul> <br>
<br>
Arylalkanoic acids 
<ul> 
<li><b>Diclofenac</b></li> 
<li>Aceclofenac</li> 
<li>Acemetacin</li> 
<li>Alclofenac</li> 
<li>Bromfenac</li> 
<li>Etodolac</li> 
<li>Indometacin</li> 
<li>Indometacin farnesil</li> 
<li>Nabumetone</li> 
<li>Oxametacin</li> 
<li>Proglumetacin</li> 
<li>Sulindac</li> 
<li>Tolmetin</li> </ul> <br>
<br>
2-Arylpropionic acids<br>
 (profens) 
<ul> 
<li><b>Ibuprofen</b></li> 
<li>Alminoprofen</li> 
<li>Benoxaprofen</li> 
<li>Carprofen</li> 
<li>Dexibuprofen</li> 
<li>Dexketoprofen</li> 
<li>Fenbufen</li> 
<li>Fenoprofen</li> 
<li>Flunoxaprofen</li> 
<li>Flurbiprofen</li> 
<li>Ibuproxam</li> 
<li>Indoprofen&dagger;</li> 
<li>Ketoprofen</li> 
<li>Ketorolac</li> 
<li>Loxoprofen</li> 
<li>Miroprofen</li> 
<li>Naproxen</li> 
<li>Oxaprozin</li> 
<li>Pirprofen</li> 
<li>Suprofen</li> 
<li>Tarenflurbil</li> 
<li>Tiaprofenic acid</li> </ul> <br>
<br>
<i>N</i>-Arylanthranilic acids<br>
 (
fenamic acids) 
<ul> 
<li><b>Mefenamic acid</b></li> 
<li>Flufenamic acid</li> 
<li>Meclofenamic acid</li> 
<li>Tolfenamic acid</li> </ul> <br>
<br>
Pyrazolidine derivatives 
<ul> 
<li><b>Phenylbutazone</b></li> 
<li>Ampyrone</li> 
<li>Azapropazone</li> 
<li>Clofezone</li> 
<li>Kebuzone</li> 
<li>Metamizole</li> 
<li>Mofebutazone</li> 
<li>Oxyphenbutazone</li> 
<li>Phenazone</li> 
<li>Sulfinpyrazone</li> </ul> <br>
<br>
Oxicams 
<ul> 
<li><b>Piroxicam</b></li> 
<li>Droxicam</li> 
<li>Lornoxicam</li> 
<li>Meloxicam</li> 
<li>Tenoxicam</li> 
<li>Ampiroxicam</li> </ul> <br>
<br>
COX-2 inhibitors 
<ul> 
<li><b>Celecoxib</b></li> 
<li>Deracoxib&Dagger;</li> 
<li>Etoricoxib</li> 
<li>Firocoxib&Dagger;</li> 
<li>Lumiracoxib&dagger;</li> 
<li>Parecoxib</li> 
<li>Rofecoxib&dagger;</li> 
<li>Valdecoxib&dagger;</li> </ul> <br>
<br>
Sulfonanilides 
<ul> 
<li>Nimesulide</li> </ul> <br>
<br>
Topically used products 
<ul> 
<li>Bendazac</li> 
<li>Diclofenac</li> 
<li>Etofenamate</li> 
<li>Felbinac</li> 
<li>Flurbiprofen</li> 
<li>Ibuprofen</li> 
<li>Indometacin</li> 
<li>Ketoprofen</li> 
<li>Naproxen</li> 
<li>Piroxicam</li> 
<li>Suprofen</li> </ul> <br>
<br>
COX-inhibiting nitric oxide donators 
<ul> 
<li>Naproxcinod</li> </ul> <br>
<br>
Others 
<ul> 
<li>Fluproquazone</li> </ul> <br>
<br>
 Items listed in <b>bold</b> indicate 
initially developed compounds of specific groups.&dagger; Withdrawn drugs. 
&Dagger; Veterinary use medications. <br>
<br>
<br>
<br>
<br>

<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Analgesics ( N02A, N02B) <br>
<br>
<br>
Opioids<br>
<i>See 
also:</i> <b>Opioids template</b> <br>
 Opium &amp; alkaloids thereof 
<ul> 
<li>Codeine#</li> 
<li>Morphine#</li> 
<li>Opium</li> 
<li>Laudanum</li> 
<li>Paregoric</li> </ul> <br>
<br>
 Semi-synthetic opium <br>
 derivatives 
<ul> 
<li>Acetyldihydrocodeine</li> 
<li>Benzylmorphine</li> 
<li>Buprenorphine</li> 
<li>Desomorphine</li> 
<li>Dihydrocodeine</li> 
<li>Dihydromorphine</li> 
<li>Ethylmorphine</li> 
<li>Diamorphine</li> 
<li>Hydrocodone</li> 
<li>Hydromorphinol</li> 
<li>Hydromorphone</li> 
<li>Nicocodeine</li> 
<li>Nicodicodeine</li> 
<li>Nicomorphine</li> 
<li>Oxycodone</li> 
<li>Oxymorphone</li> </ul> <br>
<br>
 Synthetic opioids 
<ul> 
<li>Alphaprodine</li> 
<li>Anileridine</li> 
<li>Butorphanol</li> 
<li>Dextromoramide</li> 
<li>Dextropropoxyphene</li> 
<li>Dezocine</li> 
<li>Fentanyl</li> 
<li>Ketobemidone</li> 
<li>Levorphanol</li> 
<li>Methadone</li> 
<li>Meptazinol</li> 
<li>Nalbuphine</li> 
<li>Pentazocine</li> 
<li>Propoxyphene</li> 
<li>Propiram</li> 
<li>Pethidine</li> 
<li>Phenazocine</li> 
<li>Piminodine</li> 
<li>Piritramide</li> 
<li>Tapentadol</li> 
<li>Tilidine</li> 
<li>Tramadol</li> </ul> <br>
<br>
<br>
<br>
Pyrazolones 
<ul> 
<li>Ampyrone/Aminophenazone</li> 
<li>Metamizole</li> 
<li>Phenazone</li> 
<li>Propyphenazone</li> </ul> <br>
<br>
Cannabinoids 
<ul> 
<li>Ajulemic acid</li> 
<li>AM404</li> 
<li>Cannabidiol</li> 
<li>Cannabis</li> 
<li>Nabilone</li> 
<li>Nabiximols</li> 
<li>Tetrahydrocannabinol</li> </ul> <br>
<br>
Anilides 
<ul> 
<li>Paracetamol (acetaminophen)#</li> 
<li>Phenacetin</li> 
<li>Propacetamol</li> </ul> <br>
<br>
Non-steroidal<br>
 anti-inflammatories
<br> <i>See also:</i> <b>NSAIDs template</b> <br>
 Propionic acid class 
<ul> 
<li>Fenoprofen</li> 
<li>Flurbiprofen</li> 
<li>Ibuprofen#</li> 
<li>Ketoprofen</li> 
<li>Naproxen</li> 
<li>Oxaprozin</li> </ul> <br>
<br>
 Oxicam class 
<ul> 
<li>Meloxicam</li> 
<li>Piroxicam</li> </ul> <br>
<br>
 Acetic acid class 
<ul> 
<li>Diclofenac</li> 
<li>Indometacin</li> 
<li>Ketorolac</li> 
<li>Nabumetone</li> 
<li>Sulindac</li> 
<li>Tolmetin</li> </ul> <br>
<br>
COX-2 inhibitors <br>

<ul> 
<li>Celecoxib</li> 
<li>Rofecoxib</li> 
<li>Valdecoxib</li> 
<li>Parecoxib</li> 
<li>Lumiracoxib</li> </ul> <br>
<br>
 Anthranilic acid <br>
 (fenamate) class 
<ul> 
<li>Meclofenamate</li> 
<li>Mefenamic acid</li> </ul> <br>
<br>
Salicylates <br>

<ul> 
<li><strong>Aspirin (Acetylsalicylic acid)</strong>#</li> 
<li>Benorylate</li> 
<li>Diflunisal</li> 
<li>Ethenzamide</li> 
<li>Magnesium salicylate</li> 
<li>Salicin</li> 
<li>Salicylamide</li> 
<li>Salsalate</li> 
<li>Trisalate</li> 
<li>Wintergreen (Methyl salicylate)</li> </ul> <br>
<br>
<br>
<br>
Atypical, 
adjuvant and potentiators,<br>
 Metabolic agents and miscellaneous 
<ul> 
<li>Amitryptiline</li> 
<li>Befiradol</li> 
<li>Bicifadine</li> 
<li>Carisoprodol</li> 
<li>Camphor</li> 
<li>Cimetidine</li> 
<li>Clonidine</li> 
<li>Chlorzoxazone</li> 
<li>Cyclobenzaprine</li> 
<li>Duloxetine</li> 
<li>Esreboxetine</li> 
<li>Flupirtine</li> 
<li>Gabapentin</li> 
<li>Glafenine</li> 
<li>Hydroxyzine</li> 
<li>Ketamine</li> 
<li>Menthol</li> 
<li>Mephenoxalone</li> 
<li>Methocarbamol</li> 
<li>Nefopam</li> 
<li>Orphenadrine</li> 
<li>Pregabalin</li> 
<li>Proglumide</li> 
<li>Scopolamine</li> 
<li>Tebanicline</li> 
<li>Trazodone</li> 
<li>Gabapentin enacarbil</li> 
<li>Ziconotide</li> </ul> <br>
<br>

<ul> 
<li>#WHO-EM</li> 
<li>&Dagger;Withdrawn from market</li> 
<li>Clinical trials: 
<ul> 
<li>&dagger;Phase III</li> 
<li>&sect;Never to phase III</li> </ul> </li> </ul> <br>
<br>

<p>M: CNS</p> 
<p>anat(n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp</p> 
<p>noco(m/d/e/h/v/s)/cong/tumr, sysi/epon, injr</p> 
<p>proc, drug(N1A/2AB/C/3/4/7A/B/C/D)</p> <br>
<br>
<br>
<br>
<br>
<br>
<br>

<br> 
<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Acne-treating agents ( D10) <br>
<br>
<br>
Antibacterial 
<ul> 
<li>Azelaic acid</li> 
<li>Benzoyl peroxide#</li> 
<li>Blue light therapy</li> 
<li>Tea tree oil</li> </ul> <br>
<br>
Keratolytic 
<ul> 
<li>Glycolic acid</li> 
<li>Salicylic acid#</li> 
<li>Sulfur</li> 
<li>Benzoyl peroxide#</li> </ul> <br>
<br>
Anti-inflammatory 
<ul> 
<li><strong>Aspirin</strong></li> 
<li>Ibuprofen</li> 
<li>Red light therapy</li> </ul> <br>
<br>
Antibiotics 
<ul> 
<li>Clindamycin</li> 
<li>Dapsone</li> 
<li>Erythromycin</li> 
<li>Sulfacetamide</li> 
<li>Minocycline</li> 
<li>Tetracyclines</li> </ul> <br>
<br>
Hormonal 
<ul> 
<li>Antiandrogens</li> 
<li>Contraceptives</li> </ul> <br>
<br>
Retinoids 
<ul> 
<li>Adapalene</li> 
<li>Isotretinoin</li> 
<li>Motretinide</li> 
<li>Tazarotene</li> 
<li>Tretinoin</li> </ul> <br>
<br>
Other 
<ul> 
<li>Mesulfen</li> 
<li>Tioxolone</li> </ul> <br>
<br>
Combinations 
<ul> 
<li>Adapalene/benzoyl peroxide</li> 
<li>Benzoyl peroxide/clindamycin</li> 
<li>Clindamycin/tretinoin</li> 
<li>Erythromycin/isotretinoin</li> 
<li>Sulfacetamide/sulfur</li> </ul> <br>
<br>

<ul> 
<li>#WHO-EM</li> 
<li>&Dagger;Withdrawn from market</li> 
<li>Clinical trials: 
<ul> 
<li>&dagger;Phase III</li> 
<li>&sect;Never to phase III</li> </ul> </li> </ul> <br>
<br>

<p>M: SKA</p> 
<p>anat/phys/devp</p> 
<p>noco/cong/tumr, sysi/epon</p> 
<p>proc, drug(D10)</p> <br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>

<ul> 
<li>v</li> 
<li>d</li> 
<li>e</li> </ul> Salicylates <br>
<br>
<br>

<ul> 
<li>Salicylic acid</li> 
<li><strong>Aspirin</strong></li> 
<li>Aloxiprin</li> 
<li>Methyl salicylate</li> 
<li>Magnesium salicylate</li> 
<li>Ethyl salicylate</li> 
<li>Bismuth subsalicylate</li> 
<li>Sodium salicylate</li> 
<li>Salicylamide</li> 
<li>Salicin</li> 
<li>Benorilate</li> 
<li>Salsalate</li> 
<li>Ethenzamide</li> 
<li>Diflunisal</li> 
<li>Trolamine salicylate</li> 
<li>Homosalate</li> 
<li>Salicylmethylecgonine</li> 
<li>Octyl salicylate</li> 
<li>Aluminon</li> 
<li>Benzyl salicylate</li> 
<li>Copper aspirinate</li> 
<li>Potassium salicylate</li> </ul> <br>
<br>
<br>
<br>

<p> </p> <br>
 Retrieved from &quot; 
http://en.wikipedia.org/w/index.php?title=Aspirin&amp;oldid=476219393&quot; <br>
Categories: 
<ul> 
<li>Aspirin</li> 
<li>Non-steroidal anti-inflammatory drugs</li> 
<li>Antiplatelet drugs</li> 
<li>Benzoic acids</li> 
<li>Equine medications</li> 
<li>Salicylates</li> 
<li>World Health Organization essential medicines</li> 
<li>Acetate esters</li> </ul>  Hidden categories: 
<ul> 
<li>All articles lacking reliable references</li> 
<li>Articles lacking reliable references from May 2011</li> 
<li>Articles with German language external links</li> 
<li>Good articles</li> 
<li>All articles with unsourced statements</li> 
<li>Articles with unsourced statements from November 2010</li> 
<li>Articles containing potentially dated statements from 2010</li> 
<li>All articles containing potentially dated statements</li> 
<li>All articles that may contain original research</li> 
<li>Articles that may contain original research from March 2011</li> 
<li>All pages needing factual verification</li> 
<li>Wikipedia articles needing factual verification from May 2011</li> 
<li>Wikipedia articles needing clarification from July 2009</li> </ul> <br>

<br> <br>

<h5>Personal tools</h5> 
<ul> 
<li>Log in / create account</li> </ul> 
<h5>Namespaces</h5> 
<ul> 
<li>Article</li> 
<li>Talk</li> </ul> 
<h5>Variants</h5> 
<ul> </ul> <br>

<h5>Views</h5> 
<ul> 
<li>Read</li> 
<li>Edit</li> 
<li>View history</li> </ul> 
<h5>Actions</h5> 
<ul> </ul> 
<h5>Search</h5> <br>
<br>
<br>

<h5>Navigation</h5> 
<ul> 
<li>Main page</li> 
<li>Contents</li> 
<li>Featured content</li> 
<li>Current events</li> 
<li>Random article</li> 
<li>Donate to Wikipedia</li> </ul> 
<h5>Interaction</h5> 
<ul> 
<li>Help</li> 
<li>About Wikipedia</li> 
<li>Community portal</li> 
<li>Recent changes</li> 
<li>Contact Wikipedia</li> </ul> 
<h5>Toolbox</h5> 
<ul> 
<li>What links here</li> 
<li>Related changes</li> 
<li>Upload file</li> 
<li>Special pages</li> 
<li>Permanent link</li> 
<li>Cite this page</li> </ul> 
<h5>Print/export</h5> 
<ul> 
<li>Create a book</li> 
<li>Download as PDF</li> 
<li>Printable version</li> </ul> 
<h5>Languages</h5> 
<ul> 
<li>&#1575;&#1604;&#1593;&#1585;&#1576;&#1610;&#1577;</li> 
<li>Asturianu</li> 
<li>Az&#601;rbaycanca</li> 
<li>&#2476;&#2494;&#2434;&#2482;&#2494;</li> 
<li>B&acirc;n-l&acirc;m-g&uacute;</li> 
<li>Bosanski</li> 
<li>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1089;&#1082;&#1080;</li> 
<li>Catal&agrave;</li> 
<li>&#268;esky</li> 
<li>Dansk</li> 
<li>Deutsch</li> 
<li>Eesti</li> 
<li>&Epsilon;&lambda;&lambda;&eta;&nu;&iota;&kappa;&#940;</li> 
<li>Espa&ntilde;ol</li> 
<li>Esperanto</li> 
<li>Euskara</li> 
<li>&#1601;&#1575;&#1585;&#1587;&#1740;</li> 
<li>Fran&ccedil;ais</li> 
<li>Galego</li> 
<li>&#54620;&#44397;&#50612;</li> 
<li>&#2361;&#2367;&#2344;&#2381;&#2342;&#2368;</li> 
<li>Hrvatski</li> 
<li>Ido</li> 
<li>Bahasa Indonesia</li> 
<li>&Iacute;slenska</li> 
<li>Italiano</li> 
<li>&#1506;&#1489;&#1512;&#1497;&#1514;</li> 
<li>&#3221;&#3240;&#3277;&#3240;&#3233;</li> 
<li>&#1178;&#1072;&#1079;&#1072;&#1179;&#1096;&#1072;</li> 
<li>Krey&ograve;l ayisyen</li> 
<li>Kurd&icirc;</li> 
<li>Latvie&scaron;u</li> 
<li>Lietuvi&#371;</li> 
<li>Magyar</li> 
<li>&#1052;&#1072;&#1082;&#1077;&#1076;&#1086;&#1085;&#1089;&#1082;&#1080;</li>
<li>&#3374;&#3378;&#3375;&#3390;&#3379;&#3330;</li> 
<li>Bahasa Melayu</li> 
<li>Nederlands</li> 
<li>&#26085;&#26412;&#35486;</li> 
<li>&#8234;Norsk (bokm&aring;l)&#8236;</li> 
<li>&#8234;Norsk (nynorsk)&#8236;</li> 
<li>Polski</li> 
<li>Portugu&ecirc;s</li> 
<li>Rom&acirc;n&#259;</li> 
<li>&#1056;&#1091;&#1089;&#1089;&#1082;&#1080;&#1081;</li> 
<li>Shqip</li> 
<li>Simple English</li> 
<li>Sloven&#269;ina</li> 
<li>Sloven&scaron;&#269;ina</li> 
<li>&#1057;&#1088;&#1087;&#1089;&#1082;&#1080; / Srpski</li> 
<li>Srpskohrvatski / 
&#1057;&#1088;&#1087;&#1089;&#1082;&#1086;&#1093;&#1088;&#1074;&#1072;&#1090;&#1089;&#1082;&#1080;
</li> 
<li>Suomi</li> 
<li>Svenska</li> 
<li>&#2980;&#2990;&#3007;&#2996;&#3021;</li> 
<li>&#3652;&#3607;&#3618;</li> 
<li>T&uuml;rk&ccedil;e</li> 
<li>&#1059;&#1082;&#1088;&#1072;&#1111;&#1085;&#1089;&#1100;&#1082;&#1072;</li>
<li>&#1575;&#1585;&#1583;&#1608;</li> 
<li>Ti&#7871;ng Vi&#7879;t</li> 
<li>Walon</li> 
<li>&#1497;&#1497;&#1460;&#1491;&#1497;&#1513;</li> 
<li>&#31925;&#35486;</li> 
<li>&#381;emait&#279;&scaron;ka</li> 
<li>&#20013;&#25991;</li> </ul> <br>

<ul> 
<li> This page was last modified on 11 February 2012 at 02:28.<br>
</li> 
<li>Text is available under the Creative Commons Attribution-ShareAlike License
; additional terms may apply. SeeTerms of use for details.<br>
 Wikipedia&reg; 
is a registered trademark of theWikimedia Foundation, Inc., a non-profit 
organization.<br>
</li> 
<li>Contact us</li> </ul> 
<ul> 
<li>Privacy policy</li> 
<li>About Wikipedia</li> 
<li>Disclaimers</li> 
<li>Mobile view</li> </ul> 
<ul> 
<li> </li> 
<li> </li> </ul> 
</body>